<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenytoin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenytoin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phenytoin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9769" href="/d/html/9769.html" rel="external">see "Phenytoin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10972" href="/d/html/10972.html" rel="external">see "Phenytoin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F11284327"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular risk associated with rapid infusion (injection):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The rate of intravenous phenytoin administration should not exceed  50 mg/minute in adults and 1 to 3 mg/kg/minute (or 50 mg/minute, whichever is slower) in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering intravenous phenytoin. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F209593"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dilantin;</li>
<li>Dilantin Infatabs;</li>
<li>Phenytek;</li>
<li>Phenytoin Infatabs</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867926"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dilantin;</li>
<li>Dilantin Infatabs;</li>
<li>Dilantin-125;</li>
<li>Dilantin-30;</li>
<li>TARO-Phenytoin;</li>
<li>Tremytoine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054953"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class I-B</span>;</li>
<li>
<span class="list-set-name">Antiseizure Agent, Hydantoin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462544"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses for injection are expressed as phenytoin sodium salt. Doses for oral suspension and chewable tablets are expressed as phenytoin base.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more active drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> When converting from IV phenytoin/fosphenytoin to phenytoin oral suspension, increased serum concentration monitoring and dosages may be necessary, especially in patients receiving administration via a feeding tube.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f434ab1e-2d9f-4aab-85ab-5894bdb68c0d">Status epilepticus; neonatal seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus; neonatal seizures:</b> IV: 15 to 20 mg/kg in a single or divided dose, then begin maintenance therapy usually 12 hours after dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.2017','lexi-content-ref-621616','lexi-content-ref-7196530','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.2017','lexi-content-ref-621616','lexi-content-ref-7196530','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Phenobarbital is the preferred treatment for treatment of neonatal seizures; fosphenytoin/phenytoin may be considered for refractory seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.2017','lexi-content-ref-Sansevere.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.2017','lexi-content-ref-Sansevere.2017'])">Ref</a></span>); however, fosphenytoin is preferred over phenytoin due to lower risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-23318696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-23318696'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c5aa0b6-3984-4ca1-b571-a8eb67460863">Seizures, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, maintenance therapy:</b> IV, Oral (oral suspension): Initial: 5 mg/kg/day in 2 divided doses; usual range: 4 to 8 mg/kg/day in 2 divided doses; some patients may require dosing every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.2017','lexi-content-ref-621616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.2017','lexi-content-ref-621616'])">Ref</a></span>). <b>Note:</b> If IV therapy necessary, fosphenytoin is preferred over phenytoin due to lower risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-23318696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-23318696'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F209622"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses for capsules (extended release) and injection are expressed as phenytoin sodium salt. Doses for oral suspension and chewable tablets are expressed as phenytoin base.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more active drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>When converting from IV phenytoin/fosphenytoin to phenytoin oral suspension, increased serum concentration monitoring and dosages may be necessary, especially in patients receiving administration via a feeding tube. Dosage adjustments for non-acute seizures should typically be made no more frequently than every 7 days.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus:</b> Infants, Children, and Adolescents: Loading dose: IV: 20 mg/kg in a single or divided doses; maximum dose: 1,000 mg/dose; begin maintenance therapy usually 12 hours after dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>). An additional load of 5 to 10 mg/kg if status epilepticus is not resolved has been used; however, some experts recommend trying another agent once a total loading dose of 20 mg/kg has been given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70bd1fd0-9d8e-47fe-8cab-e4cd2b0e5907">Seizures, focal onset seizures and generalized onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, focal (partial) onset seizures and generalized onset seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose (optional, not routinely used; reserved for patients if not currently on phenytoin): IV, Oral: 15 to 20 mg/kg; if currently on phenytoin, reloading dose should be based upon serum concentrations and recent dosing history; an oral loading dose should be divided into 3 doses and administered every 2 to 4 hours to decrease GI adverse effects and to maximize oral absorption.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance therapy: IV, Oral: Initial: 5 mg/kg/day in divided doses (based upon dosage form, see below); usual range: 4 to 8 mg/kg/day; maximum daily dose: 300 mg/<b>day</b>. Some experts suggest higher maintenance doses (8 to 10 mg/kg/day) may be necessary in infants and young children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Usual dosing range</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6653035','lexi-content-ref-7359247','lexi-content-ref-8009561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6653035','lexi-content-ref-7359247','lexi-content-ref-8009561'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">6 months to 3 years: IV, Oral: 8 to 10 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">4 to 6 years: IV, Oral: 7.5 to 9 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">7 to 9 years: IV, Oral: 7 to 8 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">10 to 16 years: IV, Oral: 6 to 7 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosing interval (product specific):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Immediate-release preparations (including injection, suspension, and chewable tablets): Divide daily dose into 2 to 3 doses per day.</p>
<p style="text-indent:-2em;margin-left:10em;">Extended-release preparations: In most pediatric patients, usually dosed every 12 hours; however, in adolescent patients with sufficiently long half-life, may be dosed every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f634a32-a94f-46b6-8ab0-20208300256c">Seizure prophylaxis, traumatic brain injury</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure prophylaxis, traumatic brain injury (TBI): </b>Limited data available; efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8517559','lexi-content-ref-21381863','lexi-content-ref-15039684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8517559','lexi-content-ref-21381863','lexi-content-ref-15039684'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Current guidelines suggest that prophylactic fosphenytoin/phenytoin may be considered to reduce the incidence of early (within 7 days) posttraumatic seizures in pediatric patients with severe traumatic brain injuries; it has not been shown to reduce mortality, the risk of long-term seizures nor improve neurologic outcome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30830016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30830016'])">Ref</a></span>); fosphenytoin is preferred over phenytoin if available due to lower risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-21381863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-21381863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Initial: 18 to 20 mg/kg over 20 minutes, followed by 6 mg/kg/day divided every 8 hours (Young 2004; manufacturer's labeling); dosing reported in a double-blind, placebo-controlled trial of 102 pediatric patients (n=46 treatment group; median age: 6.4 years); prophylaxis was used for 48 hours in the trials and showed no significant difference in seizure frequency between groups; however, the trial was stopped early due to a very low seizure frequency among both study groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15039684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15039684'])">Ref</a></span>). One retrospective review including 133 TBI patients who received antiseizure prophylaxis (large majority received either fosphenytoin/phenytoin) reported efficacy (ie, no seizure or impact only seizure) in 125 (94%) of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21381863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21381863'])">Ref</a></span>). In another retrospective trial, reduced seizure frequency with prophylactic phenytoin use was described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8517559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8517559'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51153599"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; &lt;5% excreted as unchanged drug. Phenytoin serum concentrations may be difficult to interpret in renal failure. Monitoring of free (unbound) concentrations or adjustment to allow interpretation is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Based on adult experience, dose supplementation may be required with high-efficiency dialyzers; monitor serum concentrations. Serum concentration may be difficult to interpret in renal failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24365310','lexi-content-ref-22149658','lexi-content-ref-16970741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24365310','lexi-content-ref-22149658','lexi-content-ref-16970741'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51153600"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; undergoes hepatic metabolism and clearance may be decreased. Monitor free phenytoin levels closely. Dosage adjustments may be necessary.</p></div>
<div class="block doa drugH1Div" id="F209598"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9769" href="/d/html/9769.html" rel="external">see "Phenytoin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Before use, consider testing for HLA-B*1502 allele in patients at increased risk of developing serious cutaneous adverse reactions (ie, those of Asian ancestry, including South Asian Indian patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18637831','lexi-content-ref-18627414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18637831','lexi-content-ref-18627414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Doses for capsules (extended release) and injection are expressed as phenytoin sodium salt. Doses for oral suspension and chewable tablets are expressed as phenytoin base.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Craniotomy, seizure prophylaxis (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i>
<b>IV:</b> 15 mg/kg at a rate of ≤50 mg/minute prior to incision; maximum dose: 2 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23425733','lexi-content-ref-2711309','lexi-content-ref-Paisansathan.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23425733','lexi-content-ref-2711309','lexi-content-ref-Paisansathan.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postoperative prophylaxis:</i>
<b>IV, Oral:</b> 5 to 6 mg/kg/day in 2 to 3 divided doses; usual daily dose: 300 to 400 mg; adjust dose based on response and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2711309','lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2711309','lexi-content-ref-Schachter.1'])">Ref</a></span>). To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>). <b>Note:</b> Duration individualized based on underlying intracranial pathology and other clinical considerations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25511789','lexi-content-ref-Merli.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25511789','lexi-content-ref-Merli.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Focal (partial) onset seizures and generalized onset seizures: Note:</b> A loading dose is suggested for patients who require rapid attainment of a therapeutic serum level; in the absence of a loading dose, full effect is typically achieved after 1 to 3 weeks (ie, when steady-state serum concentrations are reached). FDA approved for generalized tonic-clonic and complex partial seizures; may be used off label for other seizure types.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fixed (nonweight-based) dosing (manufacturer's labeling):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose (optional) (phenytoin naive): <b>Oral</b> (capsule [extended release]): 1 g divided into 3 doses (eg, 400 mg, 300 mg, 300 mg) administered at 2-hour intervals; begin maintenance dose 24 hours after first loading dose. To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>Oral</b> (capsule [extended release]): Initial: 100 mg 3 to 4 times daily; adjust dose based on response and serum concentrations. After an effective maintenance dose is established, may consider converting stable patients to once-daily dosing. To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-based dosing (off-label): </i>
<b>Note: </b>May be used to individualize loading dose and estimate initial maintenance dose requirements according to body weight.</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose (optional) (phenytoin naive): <b>IV, Oral:</b> 15 mg/kg given in 1 to 3 divided doses over 24 hours; usual total loading dose is 1 to 1.5 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Jirsch.2020','lexi-content-ref-3826809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Jirsch.2020','lexi-content-ref-3826809'])">Ref</a></span>); begin maintenance dose 8 to 12 hours after loading dose. To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: <b>IV, Oral:</b> Initial: 4 to 7 mg/kg/day (usual 300 to 400 mg/day) given in 2 to 4 divided doses; adjust dose based on response and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murphy.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murphy.2016'])">Ref</a></span>). Some experts recommend initiating maintenance therapy with 5 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.1'])">Ref</a></span>). After an effective maintenance dose is established, may consider converting stable patients to once-daily dosing (ER capsule). A maximum dose has not been established; caution should be used in prescribing maintenance doses &gt;600 mg/day. To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Traumatic brain injury, prevention of early posttraumatic seizure (alternative agent) (off-label use): Note:</b> For use in select patients at elevated risk of early seizures with concerns for secondary complications. Dosing may be institution specific; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i>
<b>IV:</b> 17 to 20 mg/kg at a rate of ≤50 mg/minute; maximum dose: 2 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22030429','lexi-content-ref-23425733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22030429','lexi-content-ref-23425733'])">Ref</a></span>); begin maintenance dose 8 to 12 hours after loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i>
<b>IV, Oral:</b> 100 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22030429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22030429'])">Ref</a></span>) <b>or</b> 5 mg/kg/day (round to the nearest 100 mg) divided every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23425733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23425733'])">Ref</a></span>). To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>). <b>Note:</b> Duration of prophylaxis varies, generally short-term use (eg, ~7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27654000','lexi-content-ref-23425733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27654000','lexi-content-ref-23425733'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus (convulsive and nonconvulsive) (alternative agent): Note:</b> If available, fosphenytoin is preferred because it is better tolerated and can be administered more rapidly than phenytoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-10877039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-10877039'])">Ref</a></span>). Generally administered as part of initial therapy with or immediately after a benzodiazepine (eg, lorazepam IV) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.2020','lexi-content-ref-Jirsch.2020','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.2020','lexi-content-ref-Jirsch.2020','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose (phenytoin naive):</b>
<b>IV:</b> 20 mg/kg at a rate of 25 to 50 mg/minute in combination with a parenteral benzodiazepine (eg, lorazepam) under continuous cardiac and blood pressure monitoring; reduce infusion rate if significant adverse events occur; if necessary, may give an additional dose of 5 to 10 mg/kg 10 minutes after the loading dose; maximum total loading dose: 30 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.2020','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.2020','lexi-content-ref-22528274'])">Ref</a></span>). Begin maintenance dose 8 to 12 hours after loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose:</b>
<b>IV, Oral:</b> Initial: 4 to 7 mg/kg/day (usual 300 to 400 mg/day) given in 2 to 4 divided doses; adjust dose based on response and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murphy.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murphy.2016'])">Ref</a></span>). Some experts recommend initiating maintenance therapy with 5 mg/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.1'])">Ref</a></span>). A maximum dose has not been established; caution should be used in prescribing maintenance doses &gt;600 mg/day. (See <i>Focal (partial) onset seizures and generalized onset seizures</i> for nonweight-based maintenance dose). To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb0151f2-b846-4d1f-9ec3-d45fa9889ced">Trigeminal neuralgia, rescue therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trigeminal neuralgia, rescue therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use during oral medication titration and/or acute exacerbation of refractory trigeminal neuralgia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ho.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ho.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 250 mg to 1 g as a one-time dose <b>or</b> 15 mg/kg (maximum dose not established) over 30 to 120 minutes; administer at a rate ≤50 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ho.2021','lexi-content-ref-10512276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ho.2021','lexi-content-ref-10512276'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy:</b> In chronic therapy, phenytoin should be withdrawn gradually over 2 to 6 months or gradually transitioned to another antiseizure agent to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage form conversions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Between IV and oral capsule formulations:</i> Convert using the same total daily dose. Oral capsules are ~10% less bioavailable than injectable formulation; dosage adjustments and closer serum monitoring may be necessary. To ensure optimal absorption, individual oral doses should not exceed 400 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7408408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7408408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Between phenytoin base (oral suspension, chewable tablets) and phenytoin sodium (capsule):</i> Dosage adjustments and closer serum monitoring may be necessary when switching between formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">Conversion: Phenytoin base ~92 mg is equivalent to phenytoin sodium 100 mg.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990886"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Phenytoin is primarily metabolized by the liver to inactive metabolites with &lt;5% of active drug excreted unchanged in the urine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-383353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-383353'])">Ref</a></span>), making routine dose adjustments for kidney dysfunction unnecessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24365310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24365310'])">Ref</a></span>). Monitoring total serum phenytoin concentrations in patients with severe kidney dysfunction is not recommended due to increased free (unbound) fraction secondary to displacement by uremic toxins. Instead, free serum concentrations should be monitored in patients with severe kidney dysfunction (eg, CrCl &lt;25 mL/minute) or those receiving renal replacement therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5006870','lexi-content-ref-4815953','lexi-content-ref-5563477','lexi-content-ref-6538287','lexi-content-ref-4378402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5006870','lexi-content-ref-4815953','lexi-content-ref-5563477','lexi-content-ref-6538287','lexi-content-ref-4378402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: <b>IV, Oral:</b></b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24365310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24365310'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Extent of dialyzability is variable and may be dependent on filter type (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1149364','lexi-content-ref-24390629','lexi-content-ref-9550689','lexi-content-ref-578272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1149364','lexi-content-ref-24390629','lexi-content-ref-9550689','lexi-content-ref-578272'])">Ref</a></span>): <b>IV, Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25929593','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25929593','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In general supplementation, posthemodialysis is not necessary. However, some patients (eg, those with documented low free serum concentrations posthemodialysis, those who have frequent seizures despite medication) may require supplemental doses postdialysis guided by free serum concentration monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25929593','lexi-content-ref-24390629','lexi-content-ref-9550689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25929593','lexi-content-ref-24390629','lexi-content-ref-9550689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7440764','lexi-content-ref-4006737','lexi-content-ref-7136686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7440764','lexi-content-ref-4006737','lexi-content-ref-7136686'])">Ref</a></span>): <b>IV, Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour), unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations and of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> No initial dosage adjustment necessary. Monitor free phenytoin concentrations closely, as some removal by CRRT is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24259740','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24259740','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations and of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> No initial dosage adjustment necessary. Monitor free phenytoin concentrations closely, as some phenytoin removal by PIRRT may occur. Supplemental doses may be required in some patients (eg, those with documented low free serum concentrations post-PIRRT, those who have frequent seizures despite medication) guided by free serum concentration monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988043"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; undergoes hepatic metabolism and clearance may be decreased. Monitor free phenytoin levels closely. Dosage adjustments may be necessary.</p></div>
<div class="block arsc drugH1Div" id="F56427402"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hematologic effects, including <b>agranulocytosis</b>,<b> granulocytopenia</b>, <b>leukopenia</b>, <b>macrocytosis</b>, <b>megaloblastic anemia</b>, <b>pancytopenia</b>, <b>pure red cell aplasia, </b>and <b>thrombocytopenia</b> with or without <b>bone marrow depression</b>, have infrequently been reported with phenytoin and are rarely fatal in adult and pediatric patients. Additionally, hyper-<b>homocystinemia</b> has been reported in pediatric patients receiving phenytoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27821519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27821519'])">Ref</a></span>). The exact incidence of blood dyscrasias is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9855327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9855327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; megaloblastic anemia may occur due to folic acid deficiency. Aplastic anemia and leukopenia may occur due to direct suppression of bone marrow cell precursors. Thrombocytopenia usually occurs within the setting of other blood dyscrasias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3150279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3150279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; blood dyscrasias in general typically occur weeks to months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9855327','lexi-content-ref-3150279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9855327','lexi-content-ref-3150279'])">Ref</a></span>). Thrombocytopenia may occur within 2 to 4 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3150279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3150279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9855327','lexi-content-ref-27821519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9855327','lexi-content-ref-27821519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Folic acid deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3150279','lexi-content-ref-27821519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3150279','lexi-content-ref-27821519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin B<sub>12</sub> deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27821519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27821519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients ≥60 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9855327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9855327'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications that cause bone marrow suppression</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of adverse hematologic reaction to any drug</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension </b>and severe <b>cardiac arrhythmia</b>, such as <b>bradycardia</b>, heart block, ventricular tachycardia, and <b>ventricular fibrillation</b> progressing to asystole, cardiac arrest, and death, may occur with rapid IV administration in all ages; adverse cardiac events have also been reported at or below the recommended infusion rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6823029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6823029'])">Ref</a></span>). The incidence of hypotension and bradycardia reported with IV phenytoin in an international drug monitoring program was 0.8% and 0.02%, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31142948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31142948'])">Ref</a></span>). Cardiovascular adverse reactions were uncommon in cases of overdose of oral phenytoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26645393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26645393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Phenytoin, a Vaughan-Williams class IB antiarrhythmic drug, inhibits sodium currents, which then widens the QRS complex and slows conduction. In addition, the refractory period is shortened, and ventricular automaticity is suppressed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31142948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31142948'])">Ref</a></span>). It also has peripheral vasodilatory and negative inotropic effects, which can lower blood pressure. Rapid IV infusion rates and propylene glycol in IV phenytoin formulations at toxic dosages may lead to bradycardia and asystole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26645393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26645393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; related to IV infusion rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26645393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26645393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• IV infusion rate (should not exceed 50 mg/minute in adults [or slower in certain adults] and 1 to 3 mg/kg/minute [or 50 mg/minute, whichever is slower] in pediatric patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26645393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26645393'])">Ref</a></span>). See "Administration" for more information.</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (&gt;50 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26645393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26645393'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid cardiac and/or metabolic disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26645393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26645393'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS effects of phenytoin are concentration-dependent and can range from mild symptoms of <b>drowsiness</b>, fatigue<b>,</b> and<b> nystagmus disorder</b> to <b>ataxia</b>, incoordination, and <b>slurred speech </b>in all ages. At very high concentrations, drug-induced <b>seizure</b> activity has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29880020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29880020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: At higher serum concentrations, saturation of protein binding occurs and the amount of free phenytoin in the serum is increased. In addition, phenytoin exhibits dose-dependent, non-linear (zero-order) elimination pharmacokinetics. The enzyme system responsible for phenytoin’s hepatic metabolism is saturable at higher serum concentrations resulting in capacity limited metabolism. As a result, small increases in doses can result in substantial elevations in serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-383353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-383353'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied, related to serum phenytoin concentrations; mostly acute (hours to days) but chronic toxicity may also occur with prolonged use (~ years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6424397','lexi-content-ref-7824121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6424397','lexi-content-ref-7824121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29880020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29880020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoalbuminemia of any cause (eg, kidney or hepatic failure, malnutrition) and uremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29880020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29880020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration with CYP2C9 and 2C19 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29880020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29880020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• CYP2C9 and 2C19 genetic polymorphisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15557548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15557548'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gingival hyperplasia or overgrowth</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gingival hyperplasia</b> or overgrowth, also referred to as gingival enlargement, can occur in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21482950','lexi-content-ref-33368283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21482950','lexi-content-ref-33368283'])">Ref</a></span>). Clinical presentation includes aesthetic changes of the gingival tissues with the potential for pain, tenderness, bleeding, speech disturbances, abnormal tooth movement, problems with dental occlusions, increased dental caries, and periodontal disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8879976','lexi-content-ref-31663446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8879976','lexi-content-ref-31663446'])">Ref</a></span>). The reported prevalence is ~50% in patients with long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21482950','lexi-content-ref-8879976','lexi-content-ref-33368283','lexi-content-ref-8707974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21482950','lexi-content-ref-8879976','lexi-content-ref-33368283','lexi-content-ref-8707974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; alters extracellular matrix metabolism resulting in increased cell proliferation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31663446','lexi-content-ref-33368283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31663446','lexi-content-ref-33368283'])">Ref</a></span>). The underlying cause is unclear but is hypothesized to be multifactorial involving the drug, plaque-induced inflammatory changes in the gingival tissues, and genetic factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31663446','lexi-content-ref-33368283','lexi-content-ref-8707974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31663446','lexi-content-ref-33368283','lexi-content-ref-8707974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; may occur after 1 month of treatment but occurs most often after 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31663446','lexi-content-ref-8707974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31663446','lexi-content-ref-8707974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increased plaque index (oral hygiene) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33368283','lexi-content-ref-8707974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33368283','lexi-content-ref-8707974'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31663446','lexi-content-ref-8707974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31663446','lexi-content-ref-8707974'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity</b> including acute <b>hepatitis</b> and <b>acute</b>
<b>hepatic failure</b> have been reported in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684','lexi-content-ref-30155393','lexi-content-ref-30926241','lexi-content-ref-32280391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684','lexi-content-ref-30155393','lexi-content-ref-30926241','lexi-content-ref-32280391'])">Ref</a></span>). Phenytoin is associated with transient <b>increased serum transaminases</b>, which seem to be mostly benign (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>). Most cases of hepatotoxicity involve hypersensitivity features (eg, rash, fever, lymphadenopathy, eosinophilia) and occur as part of <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684','lexi-content-ref-21735470','lexi-content-ref-24879980','lexi-content-ref-32376339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684','lexi-content-ref-21735470','lexi-content-ref-24879980','lexi-content-ref-32376339'])">Ref</a></span>). Hepatotoxicity is generally reversible upon discontinuation of therapy and resolves within 1 to 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684','lexi-content-ref-30155393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684','lexi-content-ref-30155393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; liver injury as part of DRESS may be caused by immune-mediated mechanisms triggered by arene oxide metabolite formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684','lexi-content-ref-24879980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684','lexi-content-ref-24879980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically after 2 to 8 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30155393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30155393'])">Ref</a></span>), one study reported a median onset of 4 weeks after initiating treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Ethnicity: Black patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28762375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28762375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: High degree of cross-reactivity exists between aromatic antiseizure medications, including phenytoin, carbamazepine, phenobarbital, primidone, and oxcarbazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879980'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history: Increased probability of hepatotoxicity (as part of DRESS) in family members who develop DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenytoin is associated with a variety of delayed hypersensitivity reactions in all ages, ranging from mild with maculopapular eruption (MPE) (also known as <b>morbilliform rash</b>) to severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome/toxic epidermal necrolysis </b>(SJS/TEN),<b> drug reaction with eosinophilia and systemic symptoms </b>(DRESS) (often referred to as antiseizure medication hypersensitivity syndrome), and <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20227592','lexi-content-ref-29027197','lexi-content-ref-31997613','lexi-content-ref-22794330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20227592','lexi-content-ref-29027197','lexi-content-ref-31997613','lexi-content-ref-22794330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including maculopapular eruptions and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31708349','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31708349','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: varied. Maculopapular rash usually occurs 3 to 20 days after start of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30955419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30955419'])">Ref</a></span>). SCARs usually occur 1 to 12 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-32779747','lexi-content-ref-32469684','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-32779747','lexi-content-ref-32469684','lexi-content-ref-NICE.1'])">Ref</a></span>); reexposure may lead to more rapid onset (usually with 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-27086495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-27086495'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females: Increased risk for development of maculopapular rash (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32134161','lexi-content-ref-28927713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32134161','lexi-content-ref-28927713'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic factors: Presence of HLA-B*1502 allele increases risk of SJS/TEN in south Asian population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20235791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20235791'])">Ref</a></span>). Other HLA alleles, including HLA-B*1301 and HLA-B*51:01 have been identified as potential risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32510242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32510242'])">Ref</a></span>). CYP2C9 polymorphism may increase the risk of DRESS and SJS/TEN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32510242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32510242'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17896897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17896897'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Reactivation of viruses: Viral reactivation, in particular human herpesvirus 6 (HHV-6) reactivation may be associated with a prolonged and more severe course of DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25369238','lexi-content-ref-17854362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25369238','lexi-content-ref-17854362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: High degree of cross-reactivity exists between aromatic antiseizure medications, including phenytoin, carbamazepine, phenobarbital, primidone, and oxcarbazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32510242','lexi-content-ref-22794330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32510242','lexi-content-ref-22794330'])">Ref</a></span>). Although chemically distinct, lamotrigine is also associated with DRESS and SJS/TEN, and may be cross-reactive to phenytoin, as shown in patch test studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28396847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28396847'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Age: Younger pediatric patients &lt;12 years and older adult patients may be at risk for severe SCARs associated with aromatic antiseizure medications, including phenytoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30955419','lexi-content-ref-29501520','lexi-content-ref-22794330','lexi-content-ref-32134161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30955419','lexi-content-ref-29501520','lexi-content-ref-22794330','lexi-content-ref-32134161'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cranial irradiation: May increase the risk of TEN/SJS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15015667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15015667'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation/tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications have been associated with suicidal ideation and tendencies in adult and pediatric patients. From trials of various antiseizure medications across multiple indications, a pooled analysis showed an increased risk of suicidal thoughts/behavior, with an incidence rate of 0.43% in treated patients, regardless of indication, as compared to 0.24% of patients receiving placebo. However, the FDA meta-analysis has been criticized due to several limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>). While some antiseizure medications (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as post-ictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; peak incidence of suicidality across antiseizure medications (not specific to individual agents) has been noted to occur between 1 and 12 weeks of drug therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889','lexi-content-ref-22994856'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use in conditions other than epilepsy or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In patients with bipolar disorder, risk for repeat suicide attempt was increased in patients with alcohol/substance abuse disorder, rapid cycling, and earlier age at onset of first manic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23226860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23226860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of suicidal ideation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23226860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23226860'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F209554"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac conduction disorder (depression), circulatory shock</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis, exfoliative dermatitis, morbilliform rash, scarlatiniform rash, skin or other tissue necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased T4, increased gamma-glutamyl transferase, vitamin D deficiency (associated with chronic treatment)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, dysgeusia, nausea, swelling of lips, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Peyronie's disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Macrocytosis, megaloblastic anemia, purpuric dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (“purple glove syndrome”; edema, discoloration, and pain distal to injection site), local inflammation, local irritation, local tissue necrosis, localized tenderness</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral atrophy (elevated serum levels and/or long-term use), cerebral dysfunction (elevated serum levels and/or long-term use), confusion, dizziness, headache, insomnia, nervousness, paresthesia, peripheral neuropathy (associated with chronic treatment), twitching, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, tissue sloughing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Earnest 1983), cardiac arrhythmia (Earnest 1983), hypotension (Earnest 1983), polyarteritis nodosa (Yermakov 1983), ventricular fibrillation (Earnest 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Aziz 2010), hypertrichosis, skin rash (Kim 2020), Stevens-Johnson syndrome (Kim 2020), toxic epidermal necrolysis (Frey 2017), urticaria (Kim 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Exacerbation of porphyria (Larson 1978, Vidaurre 2017), homocysteinemia (Chandrasekaran 2017), hyperglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hyperplasia (Arya 2011, Neelathil 2014, Perlik 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, bone marrow depression, granulocytopenia, hemolytic anemia (Blackburn 1998), Hodgkin lymphoma, homocystinemia (hyperhomocystinemia) (Chandrasekaran 2017), immunoglobulin abnormality, leukopenia, lymphadenopathy, malignant lymphoma, neutropenia (Blackburn 1998), pancytopenia, pseudolymphoma (Riyaz 2015), pure red cell aplasia (Paul 2011), thrombocytopenia (Blackburn 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Chalasani 2021), cholestatic hepatitis (Chalasani 2021), hepatitis (Chalasani 2021), hepatocellular hepatitis (Chalasani 2021), hepatotoxicity (Chalasani 2021), increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Polat 2015), angioedema (Duke 2017, Polat 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Kim 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asterixis (Chi 2000), ataxia (Farrokh 2018), chorea (Gill 2018), drowsiness (Farrokh 2018), dystonia (Acar 2018), seizure (paradoxical) (Farrokh 2018), slurred speech (Farrokh 2018), suicidal ideation (Pandey 2012), suicidal tendencies (Pandey 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Lee 2013), decreased bone mineral density (Lee 2013, Meier 2011), dyskinesia (Montenegro 1999), enlargement of facial features (including coarsening of facial features) (Lefebvre 1972), osteomalacia (Palmer 1977), osteoporosis (Patil 2015), systemic lupus erythematosus (Atwater 2008), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Nystagmus disorder (Farrokh 2018)</p></div>
<div class="block coi drugH1Div" id="F209570"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation; concurrent use of delavirdine; history of prior acute hepatotoxicity attributable to phenytoin.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Additional contraindications: Sinus bradycardia, sinoatrial block, second- and third-degree heart block, Adams-Stokes syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling (oral formulation):</i> Additional contraindications (not in US labeling): Sick sinus syndrome, sinus bradycardia, sinoatrial block, second- and third-degree heart block; QT interval prolongation; Adams-Stokes syndrome; or other heart rhythm disorders</p></div>
<div class="block war drugH1Div" id="F209551"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant (intravenous administration); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation. IV formulation may cause soft tissue irritation and inflammation, and skin necrosis at IV site; avoid IV administration in small veins. The "purple glove syndrome" (ie, discoloration with edema and pain of distal limb) may occur following peripheral IV administration of phenytoin. This syndrome may or may not be associated with drug extravasation. Symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur; interventions such as fasciotomies, skin grafts, and amputation (rare) may be required. To decrease the risk of this syndrome, inject phenytoin slowly and directly into a large vein through a large gauge needle or IV catheter; follow with NS flushes through the same needle or IV catheter.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with underlying cardiac disease; IV use is contraindicated in patients with sinus bradycardia, sinoatrial block, or second- and third-degree heart block. Bradycardia and cardiac arrest have been reported with oral phenytoin administration, usually in patients with underlying cardiac disease, and have occurred at recommended doses and levels and associated with toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; phenytoin may inhibit insulin release and increase serum glucose in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; use free (unbound) serum concentrations to monitor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoalbuminemia: Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Use free (unbound) serum concentrations to monitor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Use with caution in patients with hypothyroidism; phenytoin may alter thyroid hormone serum concentrations (with chronic administration).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: May cause exacerbation of porphyria; use with caution in patients with porphyria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; use free (unbound) serum concentrations to monitor.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Critically ill patients: Use with caution in critically ill patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in patients who are debilitated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric patients: In neonatal and pediatric patients in emergent situations, fosphenytoin is preferred over phenytoin (AAP [Shenoi 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for the treatment of absence seizures, myoclonic seizures, or seizures due to hypoglycemia or other metabolic causes. Phenytoin may increase seizure frequency in patients with childhood or juvenile absence epilepsy, juvenile myoclonic epilepsy, and Dravet Syndrome; use should be avoided in these conditions (Chaves 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sustained serum concentrations: Plasma concentrations of phenytoin sustained above the optimal range may produce confusional states referred to as delirium, psychosis, or encephalopathy, or rarely, irreversible cerebellar dysfunction and/or cerebellar atrophy. Measure plasma phenytoin concentrations at the first sign of acute toxicity; dosage reduction is indicated if phenytoin concentrations are excessive; if symptoms persist, discontinue administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block dosfc drugH1Div" id="F26964803"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">The capsule dosage form represents <i>Extended Phenytoin Sodium Capsules,</i> USP, a designation differentiating the drug from <i>Prompt Phenytoin Sodium Capsules,</i> USP (no longer available) as the extended form was characterized by a slow and extended rate of absorption when the two were compared.</p></div>
<div class="block foc drugH1Div" id="F209562"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as extended phenytoin sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin: 30 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenytek: 200 mg, 300 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (2 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin: 125 mg/5 mL (237 mL) [contains alcohol, usp, fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/4 mL (4 mL); 125 mg/5 mL (4 mL, 237 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin Infatabs: 50 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenytoin Infatabs: 50 mg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block geq drugH1Div" id="F209547"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F209572"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Dilantin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Phenytek Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Phenytoin Sodium Extended Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.34 - $1.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Dilantin Infatabs Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Phenytoin Infatabs Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Phenytoin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Phenytoin Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $0.70 - $0.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Dilantin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $0.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Phenytoin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $0.16 - $0.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867927"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as extended phenytoin sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin: 30 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin: 100 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tremytoine: 50 mg/mL (2 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (2 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin-30: 30 mg/5 mL (250 mL) [contains alcohol, usp, fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin-125: 125 mg/5 mL (250 mL) [contains alcohol, usp, fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg/5 mL (237 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilantin Infatabs: 50 mg</p></div>
<div class="block admp drugH1Div" id="F52613585"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: If the daily dosage cannot be divided equally, administer the larger dose before bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">Chewable tablets: May chew thoroughly before swallowing or swallow whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension: Shake well prior to use; measure and administer dose using a calibrated oral dosing syringe (or other accurate dose-measuring device). Absorption is impaired when phenytoin suspension is given concurrently to patients who are receiving continuous nasogastric feedings. A method to resolve this interaction is to divide the daily dose of phenytoin and withhold the administration of nutritional supplements for 1 to 2 hours before and after each phenytoin dose. In patients who cannot have enteral feeds held and phenytoin therapy cannot be avoided, frequent serum concentration monitoring and increased dosages may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release capsules: May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Note:</b> Fosphenytoin may be considered for loading in patients who are in status epilepticus, hemodynamically unstable, or develop hypotension/bradycardia with IV administration of phenytoin.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Phenytoin may be administered IV directly into a large vein through a large gauge needle or IV catheter; however, it is preferred that phenytoin be administered via infusion pump either undiluted or diluted in NS to prevent exceeding the maximum infusion rate (monitor closely for extravasation during infusion). An in-line 0.22 to 0.55 micron filter is recommended for IV piggyback (IVPB) solutions due to the potential for precipitation of the solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Administer slowly, usual maximum recommended rate: 0.5 to 1 mg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-Domonoske.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-Domonoske.2017'])">Ref</a></span>). <b>Note:</b> Although the manufacturer recommends a maximum rate: 1 to 3 mg/kg/minute, a lower maximum rate of infusion of 1 mg/kg/minute has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-11411300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-11411300'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Administer slowly, maximum recommended rate: 1 to 3 mg/kg/minute or maximum rate: 50 mg/minute, whichever is slower.</p>
<p style="text-indent:-2em;margin-left:4em;">Following IV administration, NS should be injected through the same needle or IV catheter to prevent irritation. Avoid IM use due to erratic absorption, pain on injection, and precipitation of drug at injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. There is conflicting information regarding an antidote; some sources recommend not to use an antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10532013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10532013'])">Ref</a></span>), while other sources recommend hyaluronidase (see Management of Drug Extravasations for more details).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Although the manufacturer's labeling includes IM administration, in general the IM route is not a recommended route of administration in neonatal and pediatric patients and should be avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-Domonoske.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-Domonoske.2017'])">Ref</a></span>); IM should <b>NOT</b> be used for status epilepticus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>). Avoid IM administration due to severe risk of local tissue destruction and necrosis; use fosphenytoin if IM administration necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8840370','lexi-content-ref-10597754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8840370','lexi-content-ref-10597754'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F209567"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Divide daily dose into 2 to 3 doses per day; if the daily dosage cannot be divided equally, take the larger dose before retiring.</p>
<p style="text-indent:-2em;margin-left:6em;">Chewable tablets: May chew thoroughly before swallowing or swallow whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension: Shake well prior to use; measure and administer dose using a calibrated oral dosing syringe (or other accurate dose-measuring device).</p>
<p style="text-indent:-2em;margin-left:6em;">Enteral feeding tube: Administration of phenytoin with enteral nutrition and/or nutritional supplements may decrease phenytoin absorption. If possible, hold feedings for 1 to 2 hours prior to and 1 to 2 hours after phenytoin administration; divide total daily dose into 2 doses to minimize enteral nutrition interruption. Alternatively, the phenytoin dose may be increased to overcome the interaction. Regardless of the strategy used, flush feeding tubes before and after phenytoin administration, maintain consistent administration practices throughout therapy, monitor clinical response, and consider obtaining additional serum concentration levels as clinically appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8700059','lexi-content-ref-19052281','lexi-content-ref-19667002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8700059','lexi-content-ref-19052281','lexi-content-ref-19667002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Usually dosed every 12 hours; however, in patients with sufficiently long half-life, may be dosed every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER capsule should be swallowed whole. Do not crush, cut, or chew. IR capsule, chewable tablet, and oral suspension formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of altered absorption after bariatric surgery. Conversion to IR formulation should be considered for high-risk labeled and off-label clinical indications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Avoid IM administration due to severe risk of local tissue destruction and necrosis; use <b>fos</b>phenytoin if IM administration necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8840370','lexi-content-ref-10597754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8840370','lexi-content-ref-10597754'])">Ref</a></span>). The manufacturer's labeling includes IM administration; however, in general the IM route should be avoided and should <b>NOT</b> be used for status epilepticus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For patients who are in status epilepticus, hemodynamically unstable, or develop hypotension/bradycardia with IV administration of phenytoin, consider the use of <b>fos</b>phenytoin when loading instead. Although phenytoin may be administered by direct IV injection, it is preferable that phenytoin be administered via infusion pump either undiluted or diluted in NS as an IV piggyback (IVPB) to prevent exceeding the maximum infusion rate (monitor closely for extravasation during infusion). Administer directly into a large peripheral or central vein through a large-gauge catheter. Infusion must be completed within 4 hours after dilution in NS. The maximum rate of IV administration is 50 mg/minute. Highly sensitive patients (eg, elderly patients, patients with preexisting cardiovascular conditions) should receive phenytoin more slowly (eg, 20 mg/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10597754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10597754'])">Ref</a></span>). When using IV route for oral replacement, administer at slower rate as either a loading dose or by intermittent infusion. An in-line 0.22- to 0.55-micron filter is recommended for IVPB solutions due to the potential for precipitation of the solution. Following IV administration, NS should be injected through the same needle or IV catheter to prevent irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> SUBQ administration is <b>not </b>recommended because of the possibility of local tissue damage (due to high pH).</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity and apply dry warm compresses; closely monitor for tissue sloughing or compartment syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>). There is conflicting information regarding an antidote; some sources recommend not to use an antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10532013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10532013'])">Ref</a></span>) or to use hyaluronidase in refractory cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase (if appropriate):</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>)</p></div>
<div class="block hazard drugH1Div" id="F49133436"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F209585"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule, tablet: Store at 20°C to 25°C (68°F to 77°F). Protect capsules from light. Protect capsules and tablets from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Store at 20°C to 25°C (68°F to 77°F); do not freeze. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution for injection: Store at 15°C to 30°C (59°F to 86°F). Use only clear solutions free of precipitate and haziness; slightly yellow solutions may be used. Precipitation may occur if solution is refrigerated and may dissolve at room temperature. Discard any unused product.</p></div>
<div class="block meg drugH1Div" id="F11441305"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Dilantin chewable tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F084427s039s041lbl.pdf%23page%3D17&amp;token=13BPzRKCGwuqdAeKZxhtH2NeW30Y0YQaf15xxAjFKA0h7cbohVJ5aJRqykD%2FoIs93lqsCZRfg1kKpmRfJClay6R2Op6G%2BAkKJIa7lxNKQkurD9vXOwNTp1PkMYfkFv5q&amp;TOPIC_ID=12702" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/084427s039s041lbl.pdf#page=17</a></p>
<p style="text-indent:-2em;margin-left:4em;">Dilantin extended release capsules: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F084349s085lbl.pdf%23page%3D19&amp;token=qVdwfZZ%2BjS2OKQ4gI%2FCZQeMQnxLHN9LqAIWRdCd99GCy0T2vDamWZ5XYgTby6VwvjGiy6s3JRLuDSUqNChnghdCzFq0TK%2Fh3uH1W%2BwZo9n57G4LTf8Z%2Bbfvb6XkPYeNy&amp;TOPIC_ID=12702" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/084349s085lbl.pdf#page=19</a></p>
<p style="text-indent:-2em;margin-left:4em;">Dilantin-125 oral suspension: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F008762s066lbl.pdf%23page%3D19&amp;token=qC4iEmuq5qF6D4I%2BR3%2FkkV8oEoCbI82lX%2BnDL8S%2F%2B88GA3TVdcXZTa2EIuyUHx%2BLpgtAN7zRIv8ATVc00wA3ut1%2FCuTESDbHmKP9CKP6zXgt6o7bLaiYyz6NA414jepy&amp;TOPIC_ID=12702" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/008762s066lbl.pdf#page=19</a></p></div>
<div class="block usep drugH1Div" id="F53568360"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Management of generalized tonic-clonic and complex partial seizures and the prevention of seizures following head trauma/neurosurgery (FDA approved in pediatric patients [age not specified] and adults). Has also been used for simple partial seizures; ventricular arrhythmias, including those associated with digitalis intoxication, prolonged QT interval, and surgical repair of congenital heart diseases in children.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Short-term management of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery when oral administration of phenytoin is not possible (FDA approved in neonatal and pediatric patients [age not specified] and adults).</p></div>
<div class="block mst drugH1Div" id="F209653"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Phenytoin may be confused with phenelzine, phentermine, PHENobarbital</p>
<p style="text-indent:-2em;margin-left:4em;">Dilantin may be confused with Dilaudid, dilTIAZem, Dipentum</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dilantin [US, Canada, and multiple international markets] may be confused with Dolantine brand name for pethidine [Belgium]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F209639"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP1A2 (weak), CYP2B6 (weak), CYP3A4 (strong), P-glycoprotein/ABCB1, UGT1A1, UGT1A4</p></div>
<div class="block dri drugH1Div" id="F209556"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Fosphenytoin-Phenytoin may decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Adagrasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Adagrasib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Increase the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of the P-gp inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Albendazole: Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May decrease the serum concentration of Fosphenytoin-Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alfacalcidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and strong CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alpelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Phenytoin may decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Apixaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artesunate: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of Artesunate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Atazanavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bazedoxifene: Phenytoin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Berotralstat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative antiseizure drug with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bisoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bleomycin: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Decrease brexpiprazole to original dose over 1 to 2 weeks if the strong CYP3A4 inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Brivaracetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: Fosphenytoin-Phenytoin may decrease the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Butorphanol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabazitaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: UGT1A1 Inducers may decrease the serum concentration of Cabotegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Management: Consider alternatives to this combination when possible. If combined, monitor for increased phenytoin concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: Phenytoin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Cannabidiol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Fosphenytoin-Phenytoin may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Fosphenytoin-Phenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carmustine: May decrease the serum concentration of Fosphenytoin-Phenytoin. Management: Consider alternatives to fosphenytoin-phenytoin in carmustine treated patients. If combined, monitor closely for reduced phenytoin concentrations and increase fosphenytoin-phenytoin doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CeFAZolin: May increase the serum concentration of Phenytoin. Specifically, the ratio of free phenytoin to total phenytoin may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cenobamate: Fosphenytoin-Phenytoin may decrease the serum concentration of Cenobamate. Cenobamate may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Gradually reduce the dose of fosphenytoin/phenytoin by up to 50% as the dose of cenobamate is being titrated up. Monitor phenytoin levels closely; higher doses of cenobamate may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Phenytoin may decrease the serum concentration of Chloramphenicol (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlordiazePOXIDE: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorpheniramine: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: CYP3A4 Inducers (Strong) may decrease the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider using an alternative H<sub>2</sub>-antagonist to avoid this interaction. Monitor for toxic effects of hydantoin antiseizure drugs if cimetidine is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May diminish the therapeutic effect of Phenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.  Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May decrease the serum concentration of Phenytoin. Management: Administer phenytoin at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: May enhance the hepatotoxic effect of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Monitor closely for reduced cyclosporine concentrations when combined with strong CYP3A4 inducers. Cyclosporine dose increases will likely be required to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Weak): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Weak): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with P-glycoprotein inducers whenever possible.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): May enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Darolutamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid concurrent use of dasatinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: UGT1A1 Inducers may decrease the serum concentration of Deferasirox.  Management: Avoid concomitant use of deferasirox and UGT1A1 inducers when possible. If combined, consider a 50% increase in the initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical response to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Phenytoin may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): Phenytoin may decrease the serum concentration of DexAMETHasone (Systemic). DexAMETHasone (Systemic) may decrease the serum concentration of Phenytoin. DexAMETHasone (Systemic) may increase the serum concentration of Phenytoin.  Management: Consider dexamethasone dose increases when combined with phenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely when combined with dexamethasone, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: Fosphenytoin-Phenytoin may decrease the serum concentration of DiazePAM. DiazePAM may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May decrease the serum concentration of Fosphenytoin-Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Domperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Doravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Fosphenytoin-Phenytoin may decrease the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): Phenytoin may decrease the serum concentration of DOXOrubicin (Conventional). DOXOrubicin (Conventional) may decrease the serum concentration of Phenytoin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Phenytoin may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Duvelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Edoxaban.  Management: Avoid coadministration of edoxaban and P-glycoprotein (P-gp) inducers if possible. If concomitant use is required, be aware the edoxaban efficacy may be decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: Fosphenytoin-Phenytoin may decrease the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: Fosphenytoin-Phenytoin may decrease the serum concentration of Elagolix. Elagolix may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Elagolix, Estradiol, and Norethindrone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Encorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Enzalutamide. Management: Avoid concurrent use of phenytoin/fosphenytoin and enzalutamide whenever possible. If combined, increase enzalutamide dose to 240 mg daily. Additionally, monitor for reduced phenytoin serum concentrations and effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eravacycline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eravacycline.  Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erdafitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Erlotinib. Management: Avoid use of erlotinib with phenytoin when possible. If required, increase erlotinib dose by 50 mg increments at 2 week intervals, as tolerated, to a max of 450 mg/day. Also monitor for increased phenytoin concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eslicarbazepine: Phenytoin may decrease the serum concentration of Eslicarbazepine. Eslicarbazepine may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethosuximide: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoricoxib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoricoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Everolimus.  Management: Afinitor: Double the everolimus daily dose, using increments of 5 mg or less, with careful monitoring; multiple increments may be necessary. Zortress: Avoid if possible and monitor for decreased everolimus concentrations if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Increase the exemestane dose to 50 mg once daily in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezogabine: Fosphenytoin-Phenytoin may decrease the serum concentration of Ezogabine.  Management: Consider increasing the ezogabine dose when adding phenytoin.  Patients using this combination should be monitored closely for evidence of adequate ezogabine therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Fedratinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate. Management: Initiate felbamate at typical doses (1,200 mg/day in 3 or 4 divided doses for adults and children 14 years of age or older; 15 mg/kg/day in 3 or 4 divided doses in children 2 to 14 years of age) while reducing the phenytoin dose by 20%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Felodipine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fenfluramine.  Management: Avoid concurrent use of strong CYP3A4 inducers with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexofenadine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: Phenytoin may decrease the serum concentration of Flunarizine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May decrease the serum concentration of Phenytoin. Specifically, fosamprenavir boosted with ritonavir may decrease phenytoin concentrations. Phenytoin may decrease the serum concentration of Fosamprenavir. Specifically, phenytoin may decrease the concentration of the active metabolite amprenavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostemsavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fotemustine: Fosphenytoin-Phenytoin may decrease the serum concentration of Fotemustine. Fotemustine may decrease the serum concentration of Fosphenytoin-Phenytoin. Specifically, fotemustine may decrease concentrations of orally administered phenytoin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fruquintinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: Fosphenytoin-Phenytoin may diminish the diuretic effect of Furosemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Futibatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and strong CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase the gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer. Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gestrinone: Fosphenytoin-Phenytoin may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Gilteritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glasdegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: Fosphenytoin-Phenytoin may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid use of imatinib and strong CYP3A4 inducers when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely. Doses up to 1200 mg/day (600 mg twice daily) have been used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and strong CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products.  Management: Avoid administration of strong CYP3A4 inducers during irinotecan treatment, and substitute non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Isradipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Istradefylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivosidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible. If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketoconazole (Systemic).  Management: The use of ketoconazole concurrently with or within 2 weeks of a strong CYP3A4 inducer is not recommended. If such a combination cannot be avoided, monitor patients closely for evidence of diminished clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiseizure Agents (Sodium Channel Blockers) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Phenytoin may enhance the arrhythmogenic effect of LamoTRIgine. Phenytoin may decrease the serum concentration of LamoTRIgine.  Management: Consider the risk of serious arrhythmias or death versus benefit of this combination. For patients taking phenytoin without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If concomitant use cannot be avoided, titrate lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin intravenous infusion with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: UGT1A1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leuprolide and Norethindrone. Specifically, norethindrone concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: Fosphenytoin-Phenytoin may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Fosphenytoin-Phenytoin may diminish the therapeutic effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomefolate: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonorgestrel (IUD): CYP3A4 Inducers (Strong) may diminish the therapeutic effect of Levonorgestrel (IUD). CYP3A4 Inducers (Strong) may decrease the serum concentration of Levonorgestrel (IUD). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Strong) may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Fosphenytoin-Phenytoin may enhance the adverse/toxic effect of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: Phenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Phenytoin.  Management: Avoid once-daily administration of lopinavir/ritonavir if used together with phenytoin. If twice daily lopinavir/ritonavir is coadministered with phenytoin, monitor phenytoin levels and response to both agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Strong) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumacaftor and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurbinectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Maribavir.  Management: Increase the dose of maribavir to 1,200 mg twice daily with concomitant use of fosphenytoin or phenytoin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mebendazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Mebendazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of Fosphenytoin-Phenytoin. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If fosphenytoin/phenytoin is being used for another indication, monitor for decreased concentrations and efficacy of both phenytoin and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically, fosphenytoin-phenytoin may displace methotrexate from serum proteins, increasing the concentration of free, unbound drug.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylergonovine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methylergonovine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylfolate: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Phenytoin. A disulfiram-like reaction may occur if combined with phenytoin dosage forms that contain propylene glycol. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: Fosphenytoin-Phenytoin may decrease the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Phenytoin. Phenytoin may decrease the serum concentration of Mianserin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Oral): May increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Nelfinavir. Nelfinavir may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Fosphenytoin-Phenytoin may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nevirapine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced nevirapine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Avoid coadministration of nifedipine with strong CYP3A4 inducers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Nirmatrelvir and Ritonavir. Nirmatrelvir and Ritonavir may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inducers (Weak) may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ondansetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osilodrostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib.  Management: Avoid coadministration of osimertinib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase osimertinib to 160 mg daily. Reduce osimertinib to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Paliperidone.  Management: Monitor for reduced paliperidone effects when combined with strong inducers of both CYP3A4 and P-gp. Avoid use of these inducers with extended-release injectable paliperidone and instead manage patients with paliperidone extended-release tablets.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: Phenytoin may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with phenytoin. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if phenytoin is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pexidartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Phenytoin may enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pirtobrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant.  Management: If on a stable pitolisant dose of 8.9 mg or 17.8 mg/day and starting a strong CYP3A4 inducer, double the pitolisant dose over 7 days (ie, to either 17.8 mg/day or 35.6 mg/day, respectively). Reduce pitolisant dose by 50% when the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Platinum Derivatives: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.  Management: Avoid coadministration of ponatinib with strong CYP3A4 inducers unless the potential benefit of concomitant treatment outweighs the risk of reduced ponatinib exposure. Monitor patients for reduced ponatinib efficacy if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: UGT1A1 Inducers may decrease the serum concentration of Ponesimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Posaconazole.  Management: Concomitant use of posaconazole and fosphenytoin/phenytoin should be avoided unless the benefit to the patient outweighs the risk. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pralsetinib.  Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for agranulocytosis may be increased. Fosphenytoin-Phenytoin may increase serum concentrations of the active metabolite(s) of Primidone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of Propacetamol. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of its toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyridoxine: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNINE.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced quinine efficacy and treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix.  Management: Avoid use of relugolix with drugs that are both strong CYP3A4 and  P-glycoprotein (P-gp) inducer. If combined, increase the dose of relugolix to 240 mg once daily. Reduce back to 120 mg daily once the combined inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix, Estradiol, and Norethindrone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Phenytoin may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ripretinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE.  Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with strong CYP3A4 inducers. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.  Management: Consider avoiding when possible. Dose adjustments may be required. Monitor phenytoin concentrations, and for therapeutic response to phenytoin and ritonavir, particularly with any dose adjustments.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Rufinamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ruxolitinib (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: UGT1A1 Inducers may decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Samidorphan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Conventional).  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: Fosphenytoin-Phenytoin may decrease the serum concentration of Stiripentol. Stiripentol may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Avoid this combination when possible. If combined, monitor for decreased stiripentol concentrations and effects and monitor for increased phenytoin concentrations and effects. Dose adjustments of either medication may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inducer is initiated in a patient on sufentanil, consider a sufentanil dose increase and monitor for decreased sufentanil effects and opioid withdrawal symptoms.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfADIAZINE: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfamethoxazole: May increase the serum concentration of Phenytoin. Management: Avoid coadministration of phenytoin and sulfamethoxazole. If coadministered, monitor phenytoin concentrations and for evidence of phenytoin toxicity. Risk of toxicity is increased with sulfamethoxazole/trimethoprim combination product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulthiame: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, increase sunitinib dose to a max of 87.5 mg daily when treating GIST or RCC. Increase sunitinib dose to a max of 62.5 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Tacrolimus (Systemic).  Management: Monitor for decreased tacrolimus concentrations and effects when combined with strong CYP3A4 inducers. Tacrolimus dose increases will likely be needed during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction or benign prostatic hypertrophy: monitor for decreased effectiveness - no standard dose adjustment is recommended. Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Taurursodiol. Specifically, the concentrations of phenylbutyrate may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: Fosphenytoin-Phenytoin may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol.  Management: Avoid use of the tetrahydrocannabinol/cannabidiol oromucosal spray and strong CYP3A4 inducers when possible. If combined use is necessary, careful titration is recommended, notably within the two weeks following discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Fosphenytoin-Phenytoin may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa.  Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Fosphenytoin-Phenytoin may decrease the serum concentration of Thiothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Phenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tipranavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tivozanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: May decrease the protein binding of Fosphenytoin-Phenytoin. Specifically concentrations of free phenytoin may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Topiramate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Fosphenytoin-Phenytoin may decrease the serum concentration of Topotecan.  Management: Monitor topotecan response closely, and consider alternatives to phenytoin when possible. Systemic concentrations and effects of topotecan may be reduced. No specific guidelines for topotecan dose adjustment are available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Torsemide: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Strong) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin.  Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers, such as phenytoin. In addition, monitor for increased phenytoin concentrations and effects during coadministration with trazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treosulfan: May increase the serum concentration of CYP2C19 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Triamcinolone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Triazolam.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced triazolam efficacy. Substantial triazolam dose increases will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tucatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Fosphenytoin-Phenytoin may enhance the adverse/toxic effect of Valproate Products. Specifically, the risk of hepatotoxicity or hyperammonemia may be increased. Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations.  Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vigabatrin: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days. Reduce to the original vilazodone dose over 1 to 2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of VinCRIStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of VinCRIStine (Liposomal).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: May decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fosphenytoin-Phenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Fosphenytoin-Phenytoin may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Increase maintenance dose of voriconazole from 4 mg/kg to 5 mg/kg IV every 12 hours or from 200 mg to 400 mg orally every 12 hours in patients who weigh 40 kg or more or from 100 mg to 200 mg orally every 12 hours for patients who weigh less than 40 kg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If  unavoidable, increase the voxelotor dose to 2,500 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zaleplon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zanubrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ziprasidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zonisamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zonisamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F209588"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Enteral nutrition: Administration of phenytoin with enteral nutrition and/or related nutritional supplements may decrease phenytoin absorption. Management: The manufacturer recommends not to administer concomitantly with enteral feeding preparations. Multiple strategies have been proposed to avoid concomitant administration. If possible, hold feedings for 1 to 2 hours prior to and 1 to 2 hours after phenytoin administration; divide total daily dose into 2 doses to minimize enteral nutrition interruption. Alternatively, the phenytoin dose may be increased to overcome the interaction. Regardless of the strategy used, flush feeding tubes before and after phenytoin administration, maintain consistent administration practices throughout therapy, monitor clinical response, and consider obtaining additional serum concentration levels as clinically appropriate (Gilbert 1996; Williams 2008; Wohlt 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Ethanol:</p>
<p style="text-indent:-2em;margin-left:4em;">Acute use: Ethanol inhibits metabolism of phenytoin and may also increase CNS depression. Management: Monitor patients. Caution patients about effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic use: Ethanol stimulates metabolism of phenytoin. Management: Monitor patients.</p></div>
<div class="block dic drugH1Div" id="F209575"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Folic acid: Phenytoin may decrease mucosal uptake of folic acid; to avoid folic acid deficiency and megaloblastic anemia, some clinicians recommend giving patients on antiseizure medications prophylactic doses of folic acid and cyanocobalamin (Belcastro 2012). Folic acid 0.5 mg/day has been shown to reduce the incidence of phenytoin-induced gingival overgrowth in children (Arya 2011). However, folate supplementation may increase seizures in some patients (dose dependent). Discuss with health care provider prior to using any supplements.</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium: Hypocalcemia has been reported in patients taking prolonged high-dose therapy with an antiseizure medication. Some clinicians have given an additional 4,000 units/week of vitamin D (especially in those receiving poor nutrition and getting no sun exposure) to prevent hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin B: Phenytoin use has been associated with low serum concentrations of vitamin B<sub>2</sub> (riboflavin), B<sub>6</sub> (pyridoxine) and B<sub>12</sub> (cyanocobalamin), which may contribute to hyperhomocysteinemia. Hyperhomocysteinemia may contribute to cardiovascular disease, venous thromboembolic disease, dementia, neuropsychiatric symptoms and poor seizure control. Some clinicians recommend administering riboflavin, pyridoxine and cyanocobalamin supplements in patients taking phenytoin (Apeland 2003; Apeland 2008; Belcastro 2012; Bochyńska 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: Phenytoin interferes with vitamin D metabolism and osteomalacia may result; may need to supplement with vitamin D.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection may contain sodium.</p></div>
<div class="block rep_considerations drugH1Div" id="F49321214"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Effective contraception is recommended for females of reproductive potential who are not planning a pregnancy. Phenytoin may decrease the efficacy of hormonal contraceptives; consult drug interactions database for more detailed information.</p>
<p style="text-indent:0em;margin-top:2em;">Females with epilepsy who are planning a pregnancy should have baseline serum concentrations measured once or twice prior to pregnancy during a period when seizure control is optimal (Patsalos 2008).</p></div>
<div class="block pri drugH1Div" id="F209573"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Phenytoin crosses the placenta (Harden 2009a). An increased risk of congenital malformations and adverse outcomes may occur following in utero phenytoin exposure. Reported malformations include orofacial clefts, cardiac defects, dysmorphic facial features, nail/digit hypoplasia, growth abnormalities including microcephaly, and mental deficiency. Isolated cases of malignancies (including neuroblastoma) and coagulation defects in the neonate (may be life threatening) following delivery have also been reported. Maternal use of phenytoin should be avoided when possible to decrease the risk of cleft palate and poor cognitive outcomes. Polytherapy may also increase the risk of congenital malformations; monotherapy is recommended (Harden 2009b). The maternal use of folic acid throughout pregnancy is recommended to reduce the risk of major congenital malformations (Harden 2009a). Potentially life-threatening bleeding disorders in the newborn may also occur due to decreased concentrations of vitamin K-dependent clotting factors following phenytoin exposure in utero; vitamin K administration to the mother prior to delivery and the newborn after birth is recommended.</p>
<p style="text-indent:0em;margin-top:2em;">Total plasma concentrations of phenytoin are decreased in the mother during pregnancy; unbound plasma (free) concentrations are also decreased and plasma clearance is increased. Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of phenytoin in order to maintain clinical response; monitoring during pregnancy should be considered (Harden 2009a). For women with epilepsy who are planning a pregnancy in advance, baseline serum concentrations should be measured once or twice prior to pregnancy during a period when seizure control is optimal. Monitoring can then be continued once each trimester during pregnancy and postpartum; more frequent monitoring may be needed in some patients. Monitoring of unbound plasma concentrations is recommended (Patsalos 2008; Patsalos 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to phenytoin during pregnancy are encouraged to enroll themselves in the North American Antiepileptic Drug Pregnancy Registry by calling 1-888-233-2334. Additional information is available at http://aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53568349"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, liver function, suicidality (eg, suicidal thoughts, depression, behavioral changes), bone growth or bone mineral density and vitamin D status (chronic use; particularly pediatric patients).</p>
<p style="text-indent:0em;margin-top:2em;">Serum phenytoin concentrations: If available, free phenytoin concentrations should be obtained in patients with hyperbilirubinemia, renal impairment, uremia, or hypoalbuminemia; in adult patients, if free phenytoin concentrations are unavailable, the adjusted total concentration may be determined based upon equations. Trough serum concentrations are generally recommended for routine monitoring. To ensure therapeutic concentration is attained, peak serum concentrations may be measured 1 hour after the end of an IV infusion (particularly after a loading dose).</p>
<p style="text-indent:0em;margin-top:2em;">Additional monitoring with IV use: Continuous cardiac monitoring (rate, rhythm, blood pressure) and clinical observation during administration is recommended; blood pressure and pulse should be monitored every 15 minutes for 1 hour after administration with nonemergency use (Meek 1999); emergency use may require more frequent monitoring and for a longer time after administration; infusion-site reactions.</p></div>
<div class="block rerp drugH1Div" id="F53568217"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Time of sampling is dependent on the disease state being treated and the clinical condition of the patient. In general, trough concentrations should be assessed after treatment initiation, dosage changes, or the regimen changes of interacting drugs; timing of sampling is less critical in patients receiving the extended-release oral dosage form because the slow absorption minimizes the fluctuations between peak and trough concentrations (Winter 2010). Steady-state concentrations are reached in 5 to 10 days. Trough concentrations are generally recommended for routine monitoring (capsules, oral suspension, chewable tablets, and intermittent IV dosing). Daily concentration monitoring is generally not necessary and may result in incorrect dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:2em;">After a loading dose: If rapid therapeutic serum concentrations are needed, initial serum concentrations may be drawn after 1 hour (after end of IV loading dose) or within 6 to 12 hours (after last oral loading dose) to aid in determining maintenance dose or need to reload (Meek 1999; Ratanakorn 1997; Swadron 2004). Peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity).</p>
<p style="text-indent:-2em;margin-left:2em;">Total phenytoin (protein-bound plus free unbound phenytoin): May be considered in pediatric patients ≥1 month of age who are not critically ill or those patients without: Kidney or hepatic dysfunction or drug interactions that would alter the degree of protein binding. Total phenytoin measurement is more readily available and less expensive (von Winckelmann 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total phenytoin:</i> Therapeutic range:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: 8 to 15 mcg/mL (Domonoske 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: 10 to 20 mcg/mL. Some patients may require concentrations outside the suggested therapeutic range (Hiemke 2018; Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Free phenytoin: Use free unbound phenytoin concentrations in patients with kidney or hepatic dysfunction, hypoalbuminemia (eg, neonates, albumin &lt;2.5 g/dL), or critically ill children, particularly those receiving medications that may affect phenytoin protein binding (cefazolin, valproate) (Wolf 2006). Although predictive equations (eg, Winter-Tozer) may be used to estimate free phenytoin concentrations in adults, these equations have not been found to be reliable in pediatric patients (Wolf 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Free phenytoin:</i> Therapeutic range: 1 to 2 mcg/mL; this concentration is based on typical protein binding of phenytoin and correlates with a total phenytoin concentration of 10 to 20 mcg/mL (manufacturer's labeling). Pediatric patients show greater variability in protein binding compared to adults; some patients may require/demonstrate efficacy with concentrations outside the suggested therapeutic range; a study in critically ill pediatric patients demonstrated 6% to 42% of total phenytoin was available as free drug and suggested a target free phenytoin range of 0.5 to 1.4 mcg/mL (Wolf 2006). Some studies in critically ill neonates utilized a target free phenytoin concentration of 3 mcg/mL (Painter 1994; Painter 1999). Targets outside of 1 to 2 mcg/mL may not be routinely used; refer to institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Saliva samples: Saliva concentrations may also be used as an alternative for phenytoin therapeutic drug monitoring. Saliva concentrations reflect the non-protein bound phenytoin, most similar to free serum phenytoin concentrations. For patients taking immediate-release oral dosage forms (eg, chewable tablets, oral suspension, tablets), trough concentrations are preferred to minimize the risk of residual drug impacting the drug concentration following administration; ensure drug is fully rinsed from mouth before sampling. Care should be used when sampling from patients with gingivitis or gingival hyperplasia to prevent specimen contamination with blood which could falsely elevate measurements (Patsalos 2018).</p></div>
<div class="block pha drugH1Div" id="F209550"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses; prolongs effective refractory period and suppresses ventricular pacemaker automaticity, shortens action potential in the heart</p></div>
<div class="block phk drugH1Div" id="F209569"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: ~0.5 to 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Slow, variable; dependent on product formulation; decreased in neonates.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates (Painter 1978):</p>
<p style="text-indent:-2em;margin-left:6em;">GA 27 to 30 weeks: 1.2 ± 0.11 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 31 to 36 weeks: 1.17 ± 0.21 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥37 weeks: 1.22 ± 0.21 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 0.62 to 1.04 L/kg (Loughnan 1977).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;7 years: Mean: 0.56 L/kg (Curless 1976).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.52 to 0.78 L/kg (Cranford 1978; Lund 1974).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: GA 25 to 43 weeks: 61% to 91% (Painter 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: ≥85% (≤15% free).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 87.8% to 91.9% (Richens 1979).</p>
<p style="text-indent:-2em;margin-left:4em;">Others: Decreased protein binding.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Disease states resulting in a decrease in serum albumin concentration</i>: Burns, hepatic cirrhosis, nephrotic syndrome, pregnancy, cystic fibrosis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Disease states resulting in an apparent decrease in affinity of phenytoin for serum albumin</i>: Renal failure, jaundice (severe), other drugs (displacers), hyperbilirubinemia (total bilirubin &gt;15 mg/dL), CrCl &lt;25 mL/minute (free fraction is increased 2- to 3-fold in uremia).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Follows dose-dependent (Michaelis-Menten) pharmacokinetics; "apparent” or calculated half-life is dependent upon serum concentration, therefore, metabolism is best described in terms of V<sub>max</sub> (metabolic capacity) and K<sub>m</sub> (constant equal to the concentration at which the rate of metabolism is <sup>1</sup>/<sub>2</sub> of V<sub>max</sub>); V<sub>max</sub> is increased in infants &gt;6 months and children compared to adults; major metabolite (via oxidation) HPPA undergoes enterohepatic recycling and elimination in urine as glucuronides.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Formulation dependent.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: 83% to ~100% (single dose) (Kostenbauder 1975).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 100%.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (dependent on product and/or salt): Capsules: 70% to 95% (Lund 1974; Neuvonen 1979); Oral suspension: Neonates: Variable, compared to adults, absolute enteral bioavailability reduced by 25% (Al Za'abi 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: <b>Note:</b> Elimination is not first-order (ie, follows Michaelis-Menten pharmacokinetics); half-life increases with increasing phenytoin concentrations; best described using parameters such as V<sub>max</sub> and K<sub>m </sub>(Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Prolonged and highly variable particularly during the first week of life and in premature neonates; reported range varies from 6.9 to 194 hours (Bourgeois 1983; Loughnan 1977; Painter 1978; Painter 1981).</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm neonates: 75.4 ± 64.5 hours (Loughnan 1977).</p>
<p style="text-indent:-2em;margin-left:8em;">Term neonates PNA ≤1 week: 20.7 ± 11.6 hours (Loughnan 1977).</p>
<p style="text-indent:-2em;margin-left:8em;">Term neonates PNA &gt;2 weeks and Infants: 7.6 ± 3.5 hours (Loughnan 1977).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 10 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule, oral suspension: Average 22 hours (range: 7 to 42 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Chewable tablet: Average 14 hours (range: 7 to 29 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum (formulation dependent): Oral: Extended-release capsule: 4 to 12 hours; Immediate-release preparation: 1.5 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;5% as unchanged drug); as glucuronides.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Highly variable, dependent upon intrinsic hepatic function and dose administered; increased clearance and decreased serum concentrations with febrile illness. <b>Note:</b> In newborns (PNA &lt;7 days), clearance is low but rapidly accelerates to older infant levels by 4 or 5 weeks of life (Patsalos 2008).</p></div>
<div class="block phksp drugH1Div" id="F51207898"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Increased fraction of free phenytoin may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Increased fraction of free phenytoin may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance decreases ~20% in patients &gt;70 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F209576"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phentolep</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aprocom | Epamin | Etoina | Fenigramon | Fenitenk | Fenitoina denver farma | Lotoquis simple</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenhydan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Phenytoin | Phenytoin Sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Phentin | Phenyton</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diphantoine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Epilan d | Phenhydan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Epelin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Epamin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blask | Epamin | Epamin xr | Fenaten | Fenitoina | Fenitoina sodica</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Phenhydan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Phenhydan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Epamin | Fenitoina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Epamin | Fenitenk | Fenitoina nifa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenhydan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Epilog | Ipanten | Pharotoin | Phenytin | Phenytion sodium | Phenytoin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Fenitoina combino | Fenitoina ges</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenytoin | Phenytoin cox | Phenytoin hikma</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Ditoin | Phenytoin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenhydan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Curelepz | Decatona | Dilantin | Ikaphen | Kutoin | Movileps | Natrium fenitoina | Phenilep | Phenytoin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenytoin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Epanutin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">C Toin | Dilantin | Epsotoin | Eptoin | Fentoin | Gentoin | Phenykem | Phenytoin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fenitoina Hikma</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phentolep | Phenytoin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Epatoina | Peniton | Peton | Phenytoin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phentolep</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phentolep</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenhydan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diphantoine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenhydan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Epamin | Fenaten | Feniffler | Fenitoina | Hidantoina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Ditoin | Epanutin | Phenytoin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diphantoine | Epanutin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Epinat</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dilantin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Epamin | Epamin xr | Fenitoina | Phenostal 100</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Sriphen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Epitoin | Phenton-s</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Epanutin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Extended phenytoin sodium | Phenytek | Phenytoin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Fenitoina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clerin | Epamin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Epanutin Ready-Mixed | Fentex | Phentolep</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Phenytoin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dilantin | Phenytoin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Epanutin | Hydanphen | Phenhydan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Phenhydan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dantoin | Denyl | Dilantin | Diphenylhydantoin | Ditoin | Ditomed | Fenitoina rubio | Molantin | Pepsytoin | Phenytoin | Phenytoin KP</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Phentolep</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aleviatin sodium | Dilantin | Epileptin | Hydantin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Tophen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Antepil | Comitoina Simple | Difenilhidantoina | Epanutin | Fenitoina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Difenilhidantoina | Dilantin | Epamin | Fenitoina | Fentoinal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Epanutin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3994563">
<a name="3994563"></a>Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. <i>Arch Neurol.</i> 1985;42(5):468-471. doi:10.1001/archneur.1985.04060050066010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/3994563/pubmed" id="3994563" target="_blank">3994563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30102491">
<a name="30102491"></a>Acar T, Alkan G, Çaksen H, et al. Phenytoin induced dystonia. <i>Turk J Pediatr</i>. 2018;60(1):111-112. doi:10.24953/turkjped.2018.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/30102491/pubmed" id="30102491" target="_blank">30102491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1149364">
<a name="1149364"></a>Adler DS, Martin E, Gambertoglio JG, Tozer TN, Spire JP. Hemodialysis of phenytoin in a uremic patient. <i>Clin Pharmacol Ther.</i> 1975;18(1):65-69. doi:10.1002/cpt197518165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/1149364/pubmed" id="1149364" target="_blank">1149364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15015667">
<a name="15015667"></a>Aguiar D, Pazo R, Durán I, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. <i>J Neurooncol</i>. 2004;66(3):345-350. doi:10.1023/b:neon.0000014538.31561.bc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/15015667/pubmed" id="15015667" target="_blank">15015667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25369238">
<a name="25369238"></a>Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. <i>Br J Dermatol</i>. 2015;172(4):1090-1095. doi:10.1111/bjd.13512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/25369238/pubmed" id="25369238" target="_blank">25369238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18591503">
<a name="18591503"></a>Ahn JE, Cloyd JC, Brundage RC, et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. <i>Neurology</i>. 2008;71(1):38-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18591503/pubmed" id="18591503" target="_blank">18591503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17164696">
<a name="17164696"></a>Al Za'abi M, Lanner A, Xiaonian X, Donovan T, Charles B. Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. <i>Ther Drug Monit</i>. 2006;28(6):793-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/17164696/pubmed" id="17164696" target="_blank">17164696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4032590">
<a name="4032590"></a>Anders RJ, Wang E, Radhakrishnan J, Sharifi R, Lee M. Overflow urinary incontinence due to carbamazepine. <i>J Urol</i>. 1985;134(4):758-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/4032590/pubmed" id="4032590" target="_blank">4032590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15557548">
<a name="15557548"></a>Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. <i>Neurology</i>. 2004;63(10 suppl 4):S3-S8. doi:10.1212/wnl.63.10_suppl_4.s3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/15557548/pubmed" id="15557548" target="_blank">15557548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9066931">
<a name="9066931"></a>Anderson GD, Pak C, Doane KW, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. <i>Ann Pharmacother</i>. 1997;31(3):279-284. doi:10.1177/106002809703100301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9066931/pubmed" id="9066931" target="_blank">9066931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18644700">
<a name="18644700"></a>Apeland T, Frøyland ES, Kristensen O, Strandjord RE, Mansoor MA. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins. <i>Epilepsy Res</i>. 2008;82(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18644700/pubmed" id="18644700" target="_blank">18644700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766014">
<a name="12766014"></a>Apeland T, Mansoor MA, Pentieva K, McNulty H, Strandjord RE. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. <i>Clin Chem</i>. 2003;49(6 Pt 1):1005-1008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/12766014/pubmed" id="12766014" target="_blank">12766014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482950">
<a name="21482950"></a>Arya R, Gulati S, Kabra M, et al, “Folic Acid Supplementation Prevents Phenytoin-induced Gingival Overgrowth in Children,” <i>Neurology</i>, 2011, 76(15):1338-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/21482950/pubmed" id="21482950" target="_blank">21482950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24365310">
<a name="24365310"></a>Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. <i>Handb Clin Neurol</i>. 2014;119:417-432. doi:10.1016/B978-0-7020-4086-3.00027-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/24365310/pubmed" id="24365310" target="_blank">24365310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18935900">
<a name="18935900"></a>Atwater BD, Ai Z, Wolff MR. Fulminant myopericarditis from phenytoin-induced systemic lupus erythematosus. <i>WMJ</i>. 2008;107(6):298-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18935900/pubmed" id="18935900" target="_blank">18935900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20227592">
<a name="20227592"></a>Aziz N, Toerge S, Nigra T. Phenytoin-induced acute generalized exanthemous pustulosis. <i>J Am Acad Dermatol</i>. 2010;62(4):718-719. doi:10.1016/j.jaad.2008.10.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/20227592/pubmed" id="20227592" target="_blank">20227592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25929593">
<a name="25929593"></a>Bansal AD, Hill CE, Berns JS. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease.<i> Semin Dial</i>. 2015;28(4):404-412. doi:10.1111/sdi.12385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/25929593/pubmed" id="25929593" target="_blank">25929593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6653035">
<a name="6653035"></a>Bauer LA and Blouin RA, “Phenytoin Michaelis-Menten Pharmacokinetics in Caucasian Pediatric Patients,” <i>Clin Pharmacokinet</i>, 1983, 8(6):545-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6653035/pubmed" id="6653035" target="_blank">6653035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22824326">
<a name="22824326"></a>Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. <i>Epilepsy Res</i>. 2012;102(1-2):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22824326/pubmed" id="22824326" target="_blank">22824326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30955419">
<a name="30955419"></a>Bermeo-Ovalle A. Making rash decisions in epilepsy: evaluating hypersensitivity reactions to anti-seizure medications. <i>Epilepsy Curr</i>. 2019;19(2):96-98. doi:10.1177/1535759719835672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/30955419/pubmed" id="30955419" target="_blank">30955419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24390629">
<a name="24390629"></a>Bezzaoucha S, Merghoub A, Lamarche C, et al. Hemodialysis effects on phenytoin pharmacokinetics. <i>Eur J Clin Pharmacol.</i> 2014;70(4):499-500. doi:10.1007/s00228-013-1628-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/24390629/pubmed" id="24390629" target="_blank">24390629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18341684">
<a name="18341684"></a>Björnsson E. Hepatotoxicity associated with antiepileptic drugs. <i>Acta Neurol Scand</i>. 2008;118(5):281-290. doi:10.1111/j.1600-0404.2008.01009.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18341684/pubmed" id="18341684" target="_blank">18341684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9855327">
<a name="9855327"></a>Blackburn SC, Oliart AD, García Rodríguez LA, Pérez Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. <i>Pharmacotherapy</i>. 1998;18(6):1277-1283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9855327/pubmed" id="9855327" target="_blank">9855327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5006870">
<a name="5006870"></a>Blum MR, Riegelman S, Becker CE. Altered protein binding of diphenylhydamtoin in uremic plasma. <i>N Engl J Med</i>. 1972;286(2):109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/5006870/pubmed" id="5006870" target="_blank">5006870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22360846">
<a name="22360846"></a>Bochyńska A, Lipczyńska-Łojkowska W, Gugała-Iwaniuk M, et al. The effect of vitamin B supplementation on homocysteine metabolism and clinical state of patients with chronic epilepsy treated with carbamazepine and valproic acid. <i>Seizure</i>. 2012;21(4):276-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22360846/pubmed" id="22360846" target="_blank">22360846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17896897">
<a name="17896897"></a>Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. <i>Pharmacotherapy</i>. 2007;27(10):1425-1439. doi:10.1592/phco.27.10.1425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/17896897/pubmed" id="17896897" target="_blank">17896897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8840370">
<a name="8840370"></a>Boucher BA, Feler CA, Dean JC, et al, "The Safety, Tolerability, and Pharmacokinetics of Fosphenytoin After Intramuscular and Intravenous Administration in Neurosurgery Patients," <i>Pharmacotherapy</i>, 1996, 16(4):638-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8840370/pubmed" id="8840370" target="_blank">8840370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6681658">
<a name="6681658"></a>Bourgeois BF, Dodson WE. Phenytoin elimination in newborns. <i>Neurology</i>. 1983;33(2):173-178. doi:10.1212/wnl.33.2.173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6681658/pubmed" id="6681658" target="_blank">6681658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3150279">
<a name="3150279"></a>Brown JJ, Chun RW. Phenytoin-induced thrombocytopenia. <i>Pediatr Neurol</i>. 1986;2(2):99-101. doi:10.1016/0887-8994(86)90064-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/3150279/pubmed" id="3150279" target="_blank">3150279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879976">
<a name="8879976"></a>Brunet L, Miranda J, Farré M, Berini L, Mendieta C. Gingival enlargement induced by drugs. <i>Drug Saf</i>. 1996;15(3):219-231. doi:10.2165/00002018-199615030-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8879976/pubmed" id="8879976" target="_blank">8879976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burton.2006">
<a name="Burton.2006"></a>Burton ME, Shaw LM, Schentag JJ, Evans WE. <i>Applied Pharmacokinetics and Pharmacodynamics</i>. 4th ed. Baltimore, MD: Lippincott Williams &amp; Wilkins; 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31663446">
<a name="31663446"></a>Candotto V, Pezzetti F, Baj A, et al. Phenytoin and gingival mucosa: a molecular investigation. <i>Int J Immunopathol Pharmacol</i>. 2019;33:2058738419828259. doi:10.1177/2058738419828259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/31663446/pubmed" id="31663446" target="_blank">31663446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27654000">
<a name="27654000"></a>Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. <i>Neurosurgery</i>. 2017;80(1):6-15. doi: 10.1227/NEU.0000000000001432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/27654000/pubmed" id="27654000" target="_blank">27654000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25099164">
<a name="25099164"></a>Caudle KE, Rettie AE, Whirl-Carrillo M, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. <i>Clin Pharmacol Ther</i>. 2014;96(5):542-548. doi: 10.1038/clpt.2014.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/25099164/pubmed" id="25099164" target="_blank">25099164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24872495">
<a name="24872495"></a>Chacko LN, Abraham S. Phenytoin-induced gingival enlargement. <i>BMJ Case Rep</i>. 2014;2014:bcr2014204670. doi:10.1136/bcr-2014-204670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/24872495/pubmed" id="24872495" target="_blank">24872495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28762375">
<a name="28762375"></a>Chalasani N, Reddy KRK, Fontana RJ, et al. Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians. <i>Am J Gastroenterol</i>. 2017;112(9):1382-1388. doi:10.1038/ajg.2017.215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28762375/pubmed" id="28762375" target="_blank">28762375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27821519">
<a name="27821519"></a>Chandrasekaran S, Patil S, Suthar R, et al. Hyperhomocysteinaemia in children receiving phenytoin and carbamazepine monotherapy: a cross-sectional observational study. <i>Arch Dis Child</i>. 2017;102(4):346-351. doi:10.1136/archdischild-2016-311436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/27821519/pubmed" id="27821519" target="_blank">27821519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12525711">
<a name="12525711"></a>Chang BS, Lowenstein DH; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2003;60(1):10-16. doi: 10.1212/01.WNL.0000031432.05543.14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/12525711/pubmed" id="12525711" target="_blank">12525711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32510242">
<a name="32510242"></a>Chang WC, Hung SI, Carleton BC, Chung WH. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(8):723-734. doi:10.1080/17425255.2020.1780209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/32510242/pubmed" id="32510242" target="_blank">32510242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16302887">
<a name="16302887"></a>Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. <i>Epilepsia</i>. 2005;46 Suppl 9:133-139. doi:10.1111/j.1528-1167.2005.00325.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/16302887/pubmed" id="16302887" target="_blank">16302887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27621486">
<a name="27621486"></a>Cheng W, Kiang TK, Bring P, Ensom MH. Predictive performance of the Winter-Tozer and derivative equations for estimating free phenytoin concentration. <i>Can J Hosp Pharm</i>. 2016;69(4):269-279. doi:10.4212/cjhp.v69i4.1573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/27621486/pubmed" id="27621486" target="_blank">27621486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11030457">
<a name="11030457"></a>Chi WM, Chua KS, Kong KH. Phenytoin-induced asterixis--uncommon or under-diagnozed? <i>Brain Inj</i>. 2000;14(9):847-850. doi:10.1080/026990500421949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/11030457/pubmed" id="11030457" target="_blank">11030457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7359247">
<a name="7359247"></a>Chiba K, Ishizaki T, Miura H, et al, “Michaelis-Menten Pharmacokinetics of Diphenylhydantoin and Application in the Pediatric Age Patient,” <i>J Pediatr</i>, 1980, 96(3 Pt 1):479-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7359247/pubmed" id="7359247" target="_blank">7359247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-567761">
<a name="567761"></a>Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin: clinical and pharmacokinetic aspects. <i>Neurology</i>. 1978;28(9 Pt 1):874-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/567761/pubmed" id="567761" target="_blank">567761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-945868">
<a name="945868"></a>Curless RG, Walson PD, Carter DE. Phenytoin kinetics in children. <i>Neurology</i>. 1976;26(8):715-720. doi:10.1212/wnl.26.8.715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/945868/pubmed" id="945868" target="_blank">945868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30155393">
<a name="30155393"></a>Curry B, Mican L, Smith TL. Phenytoin-induced chronic liver enzyme elevation and hepatic fibrosis: A case report. <i>Ment Health Clin</i>. 2018;8(4):184-187. doi:10.9740/mhc.2018.07.184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/30155393/pubmed" id="30155393" target="_blank">30155393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7440764">
<a name="7440764"></a>Czajka PA, Anderson WH, Christoph RA, Banner W Jr. A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. <i>J Clin Pharmacol.</i> 1980;20(10):565-569. doi:10.1002/j.1552-4604.1980.tb01671.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7440764/pubmed" id="7440764" target="_blank">7440764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522345">
<a name="30522345"></a>DasGupta R, Alaniz C, Burghardt D. Evaluation of intravenous phenytoin and fosphenytoin loading doses: influence of obesity and sex. <i>Ann Pharmacother</i>. 2019;53(5):458-463. doi:10.1177/1060028018818785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/30522345/pubmed" id="30522345" target="_blank">30522345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22030429">
<a name="22030429"></a>Debenham S, Sabit B, Saluja RS, et al. A critical look at phenytoin use for early post-traumatic seizure prophylaxis. <i>Can J Neurol Sci</i>. 2011;38(6):896-901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22030429/pubmed" id="22030429" target="_blank">22030429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10877039">
<a name="10877039"></a>DeToledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. <i>Drug Saf</i>. 2000;22(6):459-466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10877039/pubmed" id="10877039" target="_blank">10877039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24879980">
<a name="24879980"></a>Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. <i>Semin Liver Dis</i>. 2014;34(2):145-161. doi:10.1055/s-0034-1375956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/24879980/pubmed" id="24879980" target="_blank">24879980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21735470">
<a name="21735470"></a>Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. <i>Hepatology</i>. 2011;54(4):1344-1350. doi:10.1002/hep.24527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/21735470/pubmed" id="21735470" target="_blank">21735470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22149658">
<a name="22149658"></a>Diaz A, Deliz B, Benbadis SR. The use of newer antiepileptic drugs in patients with renal failure. <i>Expert Rev Neurother</i>. 2012;12(1):99-105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22149658/pubmed" id="22149658" target="_blank">22149658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.1">
<a name="Dilantin.1"></a>Dilantin Infatabs (phenytoin) chewable tablets [prescribing information]. New York, NY: Parke-Davis; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.2">
<a name="Dilantin.2"></a>Dilantin Infatabs (phenytoin) chewable tablets USP [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.3">
<a name="Dilantin.3"></a>Dilantin Infatabs (phenytoin) suspension [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.4">
<a name="Dilantin.4"></a>Dilantin (phenytoin sodium) injection [prescribing information]. New York, NY: Pfizer Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.5">
<a name="Dilantin.5"></a>Dilantin (phenytoin sodium) extended capsule [prescribing information]. New York, NY: Parke-Davis; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.6">
<a name="Dilantin.6"></a>Dilantin (phenytoin sodium) extended capsule [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.7">
<a name="Dilantin.7"></a>Dilantin-30 Suspension (phenytoin) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.8">
<a name="Dilantin.8"></a>Dilantin-125 suspension (phenytoin) [prescribing information]. New York, NY: Pfizer; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dilantin.9">
<a name="Dilantin.9"></a>Dilantin-125 suspension (phenytoin) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.2017">
<a name="Domonoske.2017"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.2020">
<a name="Drislane.2020"></a>Drislane FW. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28681416">
<a name="28681416"></a>Duke JD, Ryan PB, Suchard MA, et al. Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. <i>Epilepsia</i>. 2017;58(8):e101-e106. doi:10.1111/epi.13828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28681416/pubmed" id="28681416" target="_blank">28681416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6823029">
<a name="6823029"></a>Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. <i>JAMA</i>. 1983;249(6):762-765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6823029/pubmed" id="6823029" target="_blank">6823029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. <i>Intensive Care Med.</i> 2004;30(1):18-32. doi:10.1007/s00134-003-2059-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12434728">
<a name="12434728"></a>Erstad BL. Which weight for weight-based dosage regimens in obese patients? <i>Am J Health Syst Pharm.</i> 2002;59:(21)2105-2110. doi: 10.1093/ajhp/59.21.2105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/12434728/pubmed" id="12434728" target="_blank">12434728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926241">
<a name="30926241"></a>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>J Hepatol</i>. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/30926241/pubmed" id="30926241" target="_blank">30926241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29880020">
<a name="29880020"></a>Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA. Antiepileptic drugs in critically ill patients. <i>Crit Care</i>. 2018;22(1):153. doi:10.1186/s13054-018-2066-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29880020/pubmed" id="29880020" target="_blank">29880020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31708349">
<a name="31708349"></a>Fowler T, Bansal AS, Lozsádi D. Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting. <i>Seizure</i>. 2019;72:61-70. doi:10.1016/j.seizure.2019.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/31708349/pubmed" id="31708349" target="_blank">31708349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9550689">
<a name="9550689"></a>Frenchie D, Bastani B. Significant removal of phenytoin during high flux dialysis with cellulose triacetate dialyzer. <i>Nephrol Dial Transplant.</i> 1998;13(3):817-818. doi:10.1093/oxfordjournals.ndt.a027878<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9550689/pubmed" id="9550689" target="_blank">9550689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29027197">
<a name="29027197"></a>Frey N, Bodmer M, Bircher A, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. <i>Epilepsia</i>. 2017;58(12):2178-2185. doi:10.1111/epi.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29027197/pubmed" id="29027197" target="_blank">29027197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33368283">
<a name="33368283"></a>Gallo C, Bonvento G, Zagotto G, Mucignat-Caretta C. Gingival overgrowth induced by anticonvulsant drugs: a cross-sectional study on epileptic patients. <i>J Periodontal Res</i>. 2021;56(2):363-369. doi:10.1111/jre.12828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/33368283/pubmed" id="33368283" target="_blank">33368283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8700059">
<a name="8700059"></a>Gilbert S, Hatton J, Magnuson B. How to minimize interaction between phenytoin and enteral feedings: two approaches. <i>Nutr Clin Pract.</i> 1996;11(1):28-31. doi:10.1177/011542659601100128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8700059/pubmed" id="8700059" target="_blank">8700059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28166164">
<a name="28166164"></a>Gill D, Lyons M, Allam F. Phenytoin induced chorea: a case report. <i>Am J Ther</i>. 2018;25(3):e390. doi:10.1097/MJT.0000000000000562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28166164/pubmed" id="28166164" target="_blank">28166164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473127">
<a name="16473127"></a>Guerrini R. Epilepsy in children. <i>Lancet</i>. 2006;367(9509):499-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/16473127/pubmed" id="16473127" target="_blank">16473127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26645393">
<a name="26645393"></a>Guldiken B, Rémi J, Noachtar S. Cardiovascular adverse effects of phenytoin. <i>J Neurol</i>. 2016;263(5):861-870. doi:10.1007/s00415-015-7967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26645393/pubmed" id="26645393" target="_blank">26645393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29501520">
<a name="29501520"></a>Guvenir H, Dibek Misirlioglu E, Civelek E, et al. The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study. <i>J Allergy Clin Immunol Pract</i>. 2018;6(6):2043-2050. doi:10.1016/j.jaip.2018.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29501520/pubmed" id="29501520" target="_blank">29501520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11411300">
<a name="11411300"></a>Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. <i>Pediatr Clin North Am</i>. 2001;48(3):683-694.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/11411300/pubmed" id="11411300" target="_blank">11411300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009b;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398680">
<a name="19398680"></a>Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009a;73(2):142-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19398680/pubmed" id="19398680" target="_blank">19398680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4006737">
<a name="4006737"></a>Hays DP, Primack WA, Abroms IF. Phenytoin clearance by continuous ambulatory peritoneal dialysis. <i>Drug Intell Clin Pharm.</i> 1985;19(6):429-431. doi:10.1177/106002808501900605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/4006737/pubmed" id="4006737" target="_blank">4006737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443. doi:10.1542/peds.2007-3284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ho.2021">
<a name="Ho.2021"></a>Ho CC, Khan SA, Whealy MA. Trigeminal neuralgia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holder.2019">
<a name="Holder.2019"></a>Holder MC, Bailey AM, Baum RA, Justice SB, Weant KA. Assessment of dose capping in phenytoin loading practices in the emergency department and the impact of an emergency medicine pharmacist. <i>J Am Coll Clin Pharm</i>. 2019:2(6):633-637. doi:10.1002/jac5.1086</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4815953">
<a name="4815953"></a>Hooper WD, Bochner F, Eadie MJ, Tyrer JH. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. <i>Clin Pharmacol Ther.</i> 1974;15(3):276-282. doi:10.1002/cpt1974153276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/4815953/pubmed" id="4815953" target="_blank">4815953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20235791">
<a name="20235791"></a>Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. <i>Pharmacogenomics</i>. 2010;11(3):349-356. doi:10.2217/pgs.09.162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/20235791/pubmed" id="20235791" target="_blank">20235791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6424397">
<a name="6424397"></a>Iivanainen M, Savolainen H. Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy. <i>Acta Neurol Scand Suppl</i>. 1983;97:49-67. doi:10.1111/j.1600-0404.1983.tb01535.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6424397/pubmed" id="6424397" target="_blank">6424397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23425733">
<a name="23425733"></a>Inaba K, Menaker J, Branco BC, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. <i>J Trauma Acute Care Surg</i>. 2013;74(3):766-771; discussion 771-773. doi: 10.1097/TA.0b013e3182826e84<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/23425733/pubmed" id="23425733" target="_blank">23425733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16970741">
<a name="16970741"></a>Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. <i>Semin Dial</i>. 2006;19(5):408-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/16970741/pubmed" id="16970741" target="_blank">16970741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25511789">
<a name="25511789"></a>Iuchi T, Kuwabara K, Matsumoto M, Kawasaki K, Hasegawa Y, Sakaida T. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. <i>J Neurol Neurosurg Psychiatry</i>. 2015;86(10):1158-1162. doi: 10.1136/jnnp-2014-308584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/25511789/pubmed" id="25511789" target="_blank">25511789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jirsch.2020">
<a name="Jirsch.2020"></a>Jirsch J, Hirsch LJ. Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7408408">
<a name="7408408"></a>Jung D, Powell JR, Walson P, Perrier D. Effect of dose on phenytoin absorption. <i>Clin Pharmacol Ther</i>. 1980;28(4):479-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7408408/pubmed" id="7408408" target="_blank">7408408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32779747">
<a name="32779747"></a>Karnes JH, Rettie AE, Somogyi AA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. <i>Clin Pharmacol Ther</i>. 2021;109(2):302-309. doi:10.1002/cpt.2008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/32779747/pubmed" id="32779747" target="_blank">32779747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29029667">
<a name="29029667"></a>Khan AM, Marvanova M. Prediction accuracy of Winter-Tozer equations to estimate free phenytoin concentrations in non-critically ill hospitalized patients. <i>Consult Pharm</i>. 2017;32(8):461-467. doi:10.4140/TCP.n.2017.461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29029667/pubmed" id="29029667" target="_blank">29029667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26825643">
<a name="26825643"></a>Kiang TK, Ensom MH. A comprehensive review on the predictive performance of the Sheiner-Tozer and derivative equations for the correction of phenytoin concentrations. <i>Ann Pharmacother</i>. 2016;50(4):311-325. doi:10.1177/1060028016628166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26825643/pubmed" id="26825643" target="_blank">26825643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997613">
<a name="31997613"></a>Kim HK, Kim DY, Bae EK, Kim DW. Adverse skin reactions with antiepileptic drugs using Korea Adverse Event Reporting System Database, 2008-2017. <i>J Korean Med Sci</i>. 2020;35(4):e17. doi:10.3346/jkms.2020.35.e17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/31997613/pubmed" id="31997613" target="_blank">31997613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22794330">
<a name="22794330"></a>Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. <i>Expert Opin Drug Saf</i>. 2012;11(5):767-778. doi:10.1517/14740338.2012.705828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22794330/pubmed" id="22794330" target="_blank">22794330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30830016">
<a name="30830016"></a>Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation guidelines, executive summary. <i>Pediatr Crit Care Med</i>. 2019;20(3):280-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/30830016/pubmed" id="30830016" target="_blank">30830016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7824121">
<a name="7824121"></a>Koppel BS, Daras M, Samkoff L. Phenytoin neurotoxicity from illicit use. <i>Neurology</i>. 1995;45(1):198. doi:10.1212/wnl.45.1.198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7824121/pubmed" id="7824121" target="_blank">7824121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1100308">
<a name="1100308"></a>Kostenbauder HB, Rapp RP, McGovren JP, et al. Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin. <i>Clin Pharmacol Ther</i>. 1975;18(4):449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/1100308/pubmed" id="1100308" target="_blank">1100308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-98734">
<a name="98734"></a>Larson AW, Wasserstrom WR, Felsher BF, Chih JC. Posttraumatic epilepsy and acute intermittent porphyria: effects of phenytoin, carbamazepine, and clonazepam. <i>Neurology</i>. 1978;28(8):824-828. doi:10.1212/wnl.28.8.824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/98734/pubmed" id="98734" target="_blank">98734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20226391">
<a name="20226391"></a>Lee RH, Lyles KW, Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. <i>Am J Geriatr Pharmacother</i>. 2010;8(1):34-46. doi:10.1016/j.amjopharm.2010.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/20226391/pubmed" id="20226391" target="_blank">20226391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2711309">
<a name="2711309"></a>Lee ST, Lui TN, Chang CN, et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. <i>Surg Neurol</i>. 1989;31(5):361-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/2711309/pubmed" id="2711309" target="_blank">2711309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5024460">
<a name="5024460"></a>Lefebvre EB, Haining RG, Labbé RF. Coarse facies, calvarial thickening and hyperphosphatasia associated with long-term anticonvulsant therapy. <i>N Engl J Med</i>. 1972;286(24):1301-1302. doi:10.1056/NEJM197206152862406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/5024460/pubmed" id="5024460" target="_blank">5024460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5563477">
<a name="5563477"></a>Letteri JM, Mellk H, Louis S, Kutt H, Durante P, Glazko A. Diphenylhydantoin metabolism in uremia. <i>N Engl J Med</i>. 1971;285(12):648-652. doi:10.1056/NEJM197109162851202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/5563477/pubmed" id="5563477" target="_blank">5563477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8517559">
<a name="8517559"></a>Lewis RJ, Yee L, Inkelis SH, et al, "Clinical Predictors of Post-Traumatic Seizures in Children With Head Trauma," <i>Ann Emerg Med</i>, 1993, 22(7):1114-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8517559/pubmed" id="8517559" target="_blank">8517559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21381863">
<a name="21381863"></a>Liesemer K, Bratton SL, Zebrack CM, Brockmeyer D, Statler KD. Early post-traumatic seizures in moderate to severe pediatric traumatic brain injury: rates, risk factors, and clinical features. <i>J Neurotrauma</i>. 2011;28(5):755-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/21381863/pubmed" id="21381863" target="_blank">21381863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7136686">
<a name="7136686"></a>Lindahl S, Westerling D. Detoxification with peritoneal dialysis and blood exchange after diphenylhydantoin intoxication. <i>Acta Paediatr Scand</i>. 1982;71(4):665-666. doi:10.1111/j.1651-2227.1982.tb09495.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7136686/pubmed" id="7136686" target="_blank">7136686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6538287">
<a name="6538287"></a>Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. <i>Neurology</i>. 1984;34(3):395-397. doi:10.1212/wnl.34.3.395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6538287/pubmed" id="6538287" target="_blank">6538287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637831">
<a name="18637831"></a>Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population [published correction appears in <i>Epilepsia</i>. 2009;50(4):971]. <i>Epilepsia</i>. 2008;49(12):2087-2091. doi: 10.1111/j.1528-1167.2008.01719.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18637831/pubmed" id="18637831" target="_blank">18637831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18627414">
<a name="18627414"></a>Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i>. 2009;50(1):1-23. doi: 10.1111/j.1528-1167.2008.01716.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18627414/pubmed" id="18627414" target="_blank">18627414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-871217">
<a name="871217"></a>Loughnan PM, Greenwald A, Purton WW, Aranda JV, Watters G, Neims AH. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. <i>Arch Dis Child</i>. 1977;52(4):302-309. doi:10.1136/adc.52.4.302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/871217/pubmed" id="871217" target="_blank">871217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4853604">
<a name="4853604"></a>Lund L, Alvan G, Berlin A, Alexanderson B. Pharmacokinetics of single and multiple doses of phenytoin in man. <i>Eur J Clin Pharmacol</i>. 1974;7(2):81-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/4853604/pubmed" id="4853604" target="_blank">4853604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-578272">
<a name="578272"></a>Martin E, Gambertoglio JG, Adler DS, Tozer TN, Roman LA, Grausz H. Removal of phenytoin by hemodialysis in uremic patients. <i>JAMA</i>. 1977;238(16):1750-1753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/578272/pubmed" id="578272" target="_blank">578272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31142948">
<a name="31142948"></a>Mathews SR, Badyal DK, Mathew R. Phenytoin-induced bradycardia and hypotension. <i>Indian J Pharmacol</i>. 2019;51(2):120-122. doi:10.4103/ijp.IJP_254_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/31142948/pubmed" id="31142948" target="_blank">31142948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10512276">
<a name="10512276"></a>McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. <i>Anesth Analg</i>. 1999;89(4):985-988. doi:10.1097/00000539-199910000-00030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10512276/pubmed" id="10512276" target="_blank">10512276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10597754">
<a name="10597754"></a>Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Panel on Nonemergency Use of Parenteral Phenytoin Products. <i>Arch Intern Med</i>. 1999;159(22):2639-2644. doi:10.1001/archinte.159.22.2639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10597754/pubmed" id="10597754" target="_blank">10597754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehrizi.2012">
<a name="Mehrizi.2012"></a>Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. <i>Medications and Myasthenia Gravis (a Reference for Health Care Professionals)</i>. Indiana University School of Medicine's Department of Neurology; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22870482">
<a name="22870482"></a>Meier C, Kraenzlin ME. Antiepileptics and bone health. <i>Ther Adv Musculoskelet Dis</i>. 2011;3(5):235-243. doi:10.1177/1759720X11410769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22870482/pubmed" id="22870482" target="_blank">22870482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merli.2021">
<a name="Merli.2021"></a>Merli GJ, Bell RD. Perioperative care of the surgical patient with neurologic disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27086495">
<a name="27086495"></a>Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. <i>Am J Med</i>. 2016;129(11):1221-1225. doi:10.1016/j.amjmed.2016.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/27086495/pubmed" id="27086495" target="_blank">27086495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10450338">
<a name="10450338"></a>Montenegro MA, Scotoni AE, Cendes F. Dyskinesia induced by phenytoin. <i>Arq Neuropsiquiatr</i>. 1999;57(2B):356-360. doi:10.1590/s0004-282x1999000300002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10450338/pubmed" id="10450338" target="_blank">10450338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10532013">
<a name="10532013"></a>Montgomery LA, Hanrahan K, Kottman K, et al. Guideline for I.V. infiltrations in pediatric patients. <i>Pediatr Nurs</i>. 1999;25(2):167-169, 173-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10532013/pubmed" id="10532013" target="_blank">10532013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32469684">
<a name="32469684"></a>Morán-Mariños C, Alva-Diaz C, De la Cruz Ramirez W, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by phenytoin re-exposure: case report and systematic review. <i>Acta Clin Belg</i>. 2020;1-9. doi:10.1080/17843286.2020.1767459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/32469684/pubmed" id="32469684" target="_blank">32469684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murphy.2016">
<a name="Murphy.2016"></a>Murphy JE. <i>Clinical Pharmacokinetics</i>. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-378503">
<a name="378503"></a>Neuvonen PJ. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. <i>Clin Pharmacokinet</i>. 1979;4(2):91-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/378503/pubmed" id="378503" target="_blank">378503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8042924">
<a name="8042924"></a>Ney GC, Lantos G, Barr WB, Schaul N. Cerebellar atrophy in patients with long-term phenytoin exposure and epilepsy. <i>Arch Neurol</i>. 1994;51(8):767-771.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8042924/pubmed" id="8042924" target="_blank">8042924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. September 3, 2014. https://www.nice.org.uk/guidance/cg183. Accessed December 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7554689">
<a name="7554689"></a>Nussinovitch M, Soen G, Volovitz B, et al, “Urinary Retention Related to Phenytoin Therapy,” <i>Clin Pediatr (Phila)</i>, 1995, 34(7):382-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7554689/pubmed" id="7554689" target="_blank">7554689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259740">
<a name="24259740"></a>Oltrogge KM, Peppard WJ, Saleh M, Regner KR, Herrmann DJ. Phenytoin removal by continuous venovenous hemofiltration. <i>Ann Pharmacother</i>. 2013;47(9):1218-1222. doi:10.1177/1060028013503131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/24259740/pubmed" id="24259740" target="_blank">24259740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3826809">
<a name="3826809"></a>Osborn HH, Zisfein J, Sparano R. Single-dose oral phenytoin loading. <i>Ann Emerg Med</i>. 1987;16(4):407-412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/3826809/pubmed" id="3826809" target="_blank">3826809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8006198">
<a name="8006198"></a>Painter MJ, Minnigh MB, Gaus L, Scher M, Brozanski B, Alvin J. Neonatal phenobarbital and phenytoin binding profiles. <i>J Clin Pharmacol</i>. 1994;34(4):312-317. doi:10.1002/j.1552-4604.1994.tb01999.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8006198/pubmed" id="8006198" target="_blank">8006198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-621616">
<a name="621616"></a>Painter MJ, Pippenger C, MacDonald H, Pitlick W. Phenobarbital and diphenylhydantoin levels in neonates with seizures. <i>J Pediatr</i>. 1978;92(2):315-319. doi:10.1016/s0022-3476(78)80034-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/621616/pubmed" id="621616" target="_blank">621616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7196530">
<a name="7196530"></a>Painter MJ, Pippenger C, Wasterlain C, et al. Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. <i>Neurology</i>. 1981;31(9):1107-1112. doi:10.1212/wnl.31.9.1107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/7196530/pubmed" id="7196530" target="_blank">7196530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10441604">
<a name="10441604"></a>Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. <i>N Engl J Med</i>. 1999;341(7):485-489. doi:10.1056/NEJM199908123410704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/10441604/pubmed" id="10441604" target="_blank">10441604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paisansathan.2019">
<a name="Paisansathan.2019"></a>Paisansathan C, Ozcan MS. Anesthesia for craniotomy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 14, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-563669">
<a name="563669"></a>Palmer KT, Smith AE, Taylor BB. Anticonvulsant-induced osteomalacia. <i>Age Ageing</i>. 1977;6(4):228-231. doi:10.1093/ageing/6.4.228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/563669/pubmed" id="563669" target="_blank">563669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23226860">
<a name="23226860"></a>Pandey AK, Gupta S. Psychiatric symptomatology, scholastics, and phenytoin. <i>Indian J Psychiatry</i>. 2012;54(3):286-287. doi:10.4103/0019-5545.102436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/23226860/pubmed" id="23226860" target="_blank">23226860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26674262">
<a name="26674262"></a>Patil MM, Sahoo J, Kamalanathan S, Pillai V. Phenytoin induced osteopathy -too common to be neglected. <i>J Clin Diagn Res</i>. 2015;9(11):OD11-OD12. doi:10.7860/JCDR/2015/15224.6820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26674262/pubmed" id="26674262" target="_blank">26674262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32376339">
<a name="32376339"></a>Patocka J, Wu Q, Nepovimova E, Kuca K. Phenytoin - An anti-seizure drug: Overview of its chemistry, pharmacology and toxicology. <i>Food Chem Toxicol</i>. 2020;142:111393. doi:10.1016/j.fct.2020.111393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/32376339/pubmed" id="32376339" target="_blank">32376339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397299">
<a name="18397299"></a>Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i>. 2008;49(7):1239-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18397299/pubmed" id="18397299" target="_blank">18397299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi: 10.1097/FTD.0000000000000546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21339664">
<a name="21339664"></a>Paul G, Sood P, Berry A, Paul BS. Pure red cell aplasia with phenytoin following traumatic brain injury. <i>Neurol India</i>. 2011;59(1):69-70. doi:10.4103/0028-3886.76866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/21339664/pubmed" id="21339664" target="_blank">21339664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8585105">
<a name="8585105"></a>Perlík F, Kolínová M, Zvárová J, Patzelová V. Phenytoin as a risk factor in gingival hyperplasia. <i>Ther Drug Monit</i>. 1995;17(5):445-448. doi:10.1097/00007691-199510000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8585105/pubmed" id="8585105" target="_blank">8585105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phenytek.1">
<a name="Phenytek.1"></a>Phenytek (phenytoin sodium) extended capsule [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peapack.1">
<a name="Peapack.1"></a>Phenytoin Infatabs (phenytoin sodium) chewable tablets [prescribing information]. Peapack, NJ: Greenstone LLC; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Phenytoin injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Phenytoin injection [prescribing information]. Eatontown, NJ: West-Ward; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peapack.2">
<a name="Peapack.2"></a>Phenytoin oral suspension, USP [prescribing information]. Peapack, NJ: Greenstone LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26148111">
<a name="26148111"></a>Polat I, Karaoglu P, Ayanoglu M, Yis U, Hiz S. Life-threatening and rare adverse effects of phenytoin. <i>Pediatr Emerg Care</i>. 2015;31(7):e3. doi:10.1097/PEC.0000000000000495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26148111/pubmed" id="26148111" target="_blank">26148111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9094065">
<a name="9094065"></a>Ratanakorn D, Kaojarern S, Phuapradit P, Mokkhavesa C. Single oral loading dose of phenytoin: a pharmacokinetics study. <i>J Neurol Sci</i>. 1997;147(1):89-92. doi:10.1016/s0022-510x(96)05314-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9094065/pubmed" id="9094065" target="_blank">9094065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4378402">
<a name="4378402"></a>Reidenberg MM, Odar-Cederlöf I, von Bahr C, Borgå O, Sjöqvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.<i> N Engl J Med.</i> 1971;285(5):264-277. doi:10.1056/NEJM197107292850506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/4378402/pubmed" id="4378402" target="_blank">4378402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-383353">
<a name="383353"></a>Richens A. Clinical pharmacokinetics of phenytoin. <i>Clin Pharmacokinet</i>. 1979;4(3):153-169. doi:10.2165/00003088-197904030-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/383353/pubmed" id="383353" target="_blank">383353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26538730">
<a name="26538730"></a>Riyaz N, Sasidharanpillai S, Aravindan KP, Nobin BK, Raghavan NT, Nikhila PK. Phenytoin induced cutaneous B cell pseudolymphoma. <i>Indian J Dermatol</i>. 2015;60(5):522. doi:10.4103/0019-5154.164437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26538730/pubmed" id="26538730" target="_blank">26538730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.1">
<a name="Schachter.1"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.2">
<a name="Schachter.2"></a>Schachter SC. Overview of the management of epilepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 9, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sansevere.2017">
<a name="Sansevere.2017"></a>Sansevere AJ. Neonatal seizures. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017: 824-828.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8707974">
<a name="8707974"></a>Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. <i>J Clin Periodontol</i>. 1996;23(3 Pt 1):165-175. doi:10.1111/j.1600-051x.1996.tb02072.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8707974/pubmed" id="8707974" target="_blank">8707974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28396847">
<a name="28396847"></a>Shiny TN, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Sharma R. Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anticonvulsants: A preliminary report. <i>World J Methodol</i>. 2017;7(1):25-32. doi:10.5662/wjm.v7.i1.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28396847/pubmed" id="28396847" target="_blank">28396847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23318696">
<a name="23318696"></a>Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. <i>J Child Neurol</i>. 2013;28(3):351-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/23318696/pubmed" id="23318696" target="_blank">23318696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9620019">
<a name="9620019"></a>Sokol DK, Dahlmann A, Dunn DW. Hyaluronidase treatment for intravenous phenytoin extravasation. <i>J Child Neurol</i>. 1998;13(5):246-247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/9620019/pubmed" id="9620019" target="_blank">9620019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28470115">
<a name="28470115"></a>Soriano VV, Tesoro EP, Kane SP. Characterization of free phenytoin concentrations in end-stage renal disease using the Winter-Tozer equation. <i>Ann Pharmacother</i>. 2017;51(8):669-674. doi:10.1177/1060028017707541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28470115/pubmed" id="28470115" target="_blank">28470115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32280391">
<a name="32280391"></a>Sridharan K, Daylami AA, Ajjawi R, Ajooz HAMA. Drug-induced liver injury in critically ill children taking antiepileptic drugs: a retrospective study. <i>Curr Ther Res Clin Exp</i>. 2020;92:100580. doi:10.1016/j.curtheres.2020.100580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/32280391/pubmed" id="32280391" target="_blank">32280391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32134161">
<a name="32134161"></a>Sukasem C, Sririttha S, Tempark T, et al. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population. <i>Pharmacoepidemiol Drug Saf</i>. 2020;29(5):565-574. doi:10.1002/pds.4979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/32134161/pubmed" id="32134161" target="_blank">32134161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8009561">
<a name="8009561"></a>Suzuki Y, Mimaki T, Cox S, et al, “Phenytoin Age-Dose-Concentration Relationship in Children,” <i>Ther Drug Monit</i>, 1994, 16(2):145-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/8009561/pubmed" id="8009561" target="_blank">8009561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15001403">
<a name="15001403"></a>Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M. A comparison of phenytoin-loading techniques in the emergency department. <i>Acad Emerg Med</i>. 2004;11(3):244-252. doi:10.1111/j.1553-2712.2004.tb02204.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/15001403/pubmed" id="15001403" target="_blank">15001403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22011984">
<a name="22011984"></a>Tate R, Rubin LM, Krajewski KC. Treatment of refractory trigeminal neuralgia with intravenous phenytoin. <i>Am J Health Syst Pharm</i>. 2011;68(21):2059-2061. doi:10.2146/ajhp100636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/22011984/pubmed" id="22011984" target="_blank">22011984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2115976">
<a name="2115976"></a>Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. <i>N Engl J Med</i>. 1990;323(8):497-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/2115976/pubmed" id="2115976" target="_blank">2115976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17854362">
<a name="17854362"></a>Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. <i>Br J Dermatol</i>. 2007;157(5):934-940. doi:10.1111/j.1365-2133.2007.08167.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/17854362/pubmed" id="17854362" target="_blank">17854362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28927713">
<a name="28927713"></a>Uribe-San-Martín R, Ciampi E, Uslar W, et al. Risk factors of early adverse drug reactions with phenytoin: A prospective inpatient cohort. <i>Epilepsy Behav</i>. 2017;76:139-144. doi:10.1016/j.yebeh.2017.08.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/28927713/pubmed" id="28927713" target="_blank">28927713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29097018">
<a name="29097018"></a>Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. <i>Pediatr Neurol</i>. 2017;77:23-36. doi:10.1016/j.pediatrneurol.2017.09.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29097018/pubmed" id="29097018" target="_blank">29097018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18956999">
<a name="18956999"></a>von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. <i>Pharmacotherapy</i>. 2008;28(11):1391-1400. doi:10.1592/phco.28.11.1391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/18956999/pubmed" id="18956999" target="_blank">18956999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11524464">
<a name="11524464"></a>Wilder BJ, Leppik I, Hietpas TJ, Cloyd JC, Randinitis EJ, Cook J. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. <i>Neurology</i>. 2001;57(4):582-589. doi:10.1212/wnl.57.4.582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/11524464/pubmed" id="11524464" target="_blank">11524464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19052281">
<a name="19052281"></a>Williams NT. Medication administration through enteral feeding tubes. <i>Am J Health Syst Pharm</i>. 2008;65(24):2347-2357. doi:10.2146/ajhp080155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19052281/pubmed" id="19052281" target="_blank">19052281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29196247">
<a name="29196247"></a>Wilson CD, Burks JD, Rodgers RB, Evans RM, Bakare AA, Safavi-Abbasi S. Early and late posttraumatic epilepsy in the setting of traumatic brain injury: a meta-analysis and review of antiepileptic management. <i>World Neurosurg</i>. 2018;110:e901-e906. doi: 10.1016/j.wneu.2017.11.116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/29196247/pubmed" id="29196247" target="_blank">29196247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Winter.2010">
<a name="Winter.2010"></a>Winter ME. <i>Basic Clinical Pharmacokinetics</i>. 5th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19667002">
<a name="19667002"></a>Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT. Recommendations for the use of medications with continuous enteral nutrition. <i>Am J Health Syst Pharm.</i> 2009;66(16):1458-1467. doi:10.2146/ajhp080632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/19667002/pubmed" id="19667002" target="_blank">19667002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16885794">
<a name="16885794"></a>Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. <i>Pediatr Crit Care Med</i>. 2006;7(5):434-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/16885794/pubmed" id="16885794" target="_blank">16885794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6131861">
<a name="6131861"></a>Yermakov VM, Hitti IF, Sutton AL. Necrotizing vasculitis associated with diphenylhydantoin: two fatal cases. <i>Hum Pathol</i>. 1983;14(2):182-184. doi:10.1016/s0046-8177(83)80248-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/6131861/pubmed" id="6131861" target="_blank">6131861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15039684">
<a name="15039684"></a>Young KD, Okada PJ, Sokolove PE, et al, "A Randomized, Double-Blinded, Placebo-Controlled Trial of Phenytoin for the Prevention of Early Posttraumatic Seizures in Children With Moderate to Severe Blunt Head Injury," <i>Ann Emerg Med</i>, 2004, 43(4):435-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/15039684/pubmed" id="15039684" target="_blank">15039684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12702 Version 627.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
